



Edison Healthcare Insight

December 2017

Maxim Jacobs


Max joined Edison's healthcare team in December 2014. Prior to this he worked as a senior analyst at Guidepoint Global. Max has also previously worked as a senior analyst at Ridgemark Capital, a sector head at Broadfin Capital and as a senior analyst at Mehta Partners. He is a CFA charter holder.

Dr Nathaniel Calloway


Nathaniel Calloway joined the healthcare team in December 2015. Before Edison, he performed healthcare investment research for a fund at Bishop Rosen and for Wainscott Capital Partners. Prior to his role as an analyst he performed molecular neuroscience research at Cornell Medical School and holds a PhD in chemistry from Cornell. He has published eight scientific papers on topics ranging from physical chemistry to immunology, and he has been recognised as an American Heart Association fellow and an American Chemical Society Medicinal Chemistry fellow.

Pooya Hemami


Pooya is a licensed optometrist with over five years of experience in life sciences equity research. Prior to joining Edison, he covered the Canadian healthcare sector as a research analyst at Desjardins Capital Markets. He holds a doctor of optometry degree from the University of Montreal, and an MBA (finance concentration) from McGill University. He received his CFA charter in 2011.

Dr John Savin


John is an analyst working on biotech, pharma, medical device and diagnostics companies. As founder CEO of Physiomics, he devised the strategy, raised funds and took the company to AIM in 2004. At Greig Middleton, John was director in charge of the pharma and biotech analyst team and worked with corporate finance on fund-raising, IPOs and corporate restructuring. He has an industry background in sales and marketing with GE Healthcare and AstraZeneca and is a co-author on a number of scientific publications.

Juan Pedro Serrate


Juan joined Edison's Healthcare team in April 2016. A veterinarian by training, he has held business positions in the healthcare sector over the past 12 years. Juan has collaborated with independent equity research firms, specialising in fundamental analysis and valuations. For more than six years, he co-managed a seed capital fund in Spain that invested in biotech start-ups and projects. Earlier in his career, he was a research fellow at the Yale University School of Medicine. He has a Master's degree in biotechnology, as well as an MBA from IESE Business School.

Dr Dennis Hulme



Dennis joined Edison in December 2014. Prior to this he worked as an analyst at BBY Stockbrokers and as a research scientist at CSIRO. Dennis was ranked number two healthcare stock picker in the 2010 StarMine Analyst Awards and has a PhD in veterinary sciences.

Dr Jonas Peciulis


Jonas joined Edison in November 2015. He is a qualified medical doctor with several years of clinical practice. He then moved into equity research as a healthcare analyst at Norne Securities, focused on Norwegian companies, and received two StarMine awards for stock picking in 2013. Most recently, he worked for a London-based life sciences venture capital company before completing his MBA degree.

Dr Susie Jana


Susie joined the team in September 2015 and has 16 years' experience in the healthcare sector. She is a qualified medical doctor, having studied medicine at UCL. She also holds an intercalated BSc in psychology. After a few years working as a junior doctor in the NHS, Susie joined the investment banking industry for six years on the sell-side covering biotechnology stocks, then mid- to large-cap pharmaceuticals at Société Générale. Most recently she worked as a buy-side analyst, covering European biotech, pharma and medtech stocks at F&C Investments for five years.

Dr Andy Smith


Andy joined the Healthcare team at Edison in November 2017 after a period as a senior principal in ICON's Pricing & Market Access consultancy. Prior to ICON he was chief investment officer at Mann Bioinvest and managed healthcare and biotech funds at AXA Framlington, SV Life Sciences, Schroders and 3i Group. Andy is a scientist by training and completed his PhD with Glaxochem after working for ICI and in the NHS. Between working as a lecturer at Guy's Medical School, he worked in R&D management at SmithKline Beecham, before moving to the Strategic Product Development group in SB Pharmaceuticals to be a global product manager. Andy also has an MBA from the University of Greenwich and teaches the finance module on the Master's in Bioscience Enterprise course at the University of Cambridge.

Dr Daniel Wilkinson


Daniel joined Edison's Healthcare team in January 2016. He spent four years at Imperial College London, where he undertook both a Master's in Chemical Biology of Health & Disease and a PhD in Biosensors and Biotechnology in Diabetes. Before this he worked at eTect, a spin-out company from the University of Leeds that was focused on biosensor technology. He is currently studying for the Investment Management Certificate (IMC).

Alice Nettleton


Alice joined Edison's Healthcare team in November 2017. Previously, she worked as a business analyst at PharmaVentures on a variety of consulting projects relating to life science transactions. Alice holds a BSc in Biomedical Sciences from King's College London and an MSc in Business Creation and Innovation in Biomedicine from Gothenburg University, and while studying has completed two internships at IP Pragmatics.

Contents

Company profiles	3
Company coverage	36

Prices at 8 December 2017

Published 14 December 2017

Welcome to the December edition of the Edison Healthcare Insight. In this edition we have profiled 65 of our healthcare companies under coverage.

Readers wishing more detail should visit our website, where reports are freely available for download (www.edisongroup.com). All profit and earnings figures shown are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison is a registered investment adviser regulated by the state of New York.

We welcome any [comments/suggestions](#) our readers may have.

Neil Shah & Maxim Jacobs

Healthcare Research

Company profiles

Prices at 8 December

US\$/£ exchange rate: 0.7458

€/£ exchange rate: 0.8793

C\$/£ exchange rate: 0.5814

A\$/£ exchange rate: 0.5615

NZ\$/£ exchange rate: 0.5105

SEK/£ exchange rate: 0.0882

DKK/£ exchange rate: 0.1182

NOK/£ exchange rate: 0.0899

JPY/£ exchange rate: 0.0066

NIS/£ exchange rate: 0.2100

CHF/£ exchange rate: 0.7520

Sector: Pharma & healthcare

Price: €5.05
Market cap: €155m
Market: FRA

Share price graph (€)

Company description

4SC is a Munich-based cancer biopharmaceutical company. Resminostat (HDAC inhibitor) is the lead candidate for cutaneous T-Cell lymphoma (pivotal study started in Q416). It has a second compound, 4SC-202 (Phase II) and a preclinical asset, 4SC-208. 4SC also has several partners including Yakult Honsha for resminostat in Japan.

Price performance

%	1m	3m	12m
Actual	(4.0)	13.4	120.9
Relative*	(2.3)	6.1	87.8

* % Relative to local index

Analyst

Dr Jonas Pecilius

4SC (VSC)

INVESTMENT SUMMARY

The equity capital raise (€41m gross) in July will fund 4SC's progressive R&D plan. Its pivotal 150-patient study with anti-cancer compound resminostat (broad spectrum-HDAC inhibitor) for CTCL has recruited more than one third of patients. Top-line data is expected in H119. Resminostat has also been licensed to Yakult Honsha in Japan, which is preparing for Phase II in biliary tract cancer based on positive data from a Phase I trial. Alongside resminostat, 4SC is currently evaluating the combination of 4SC-202 with checkpoint inhibitors in a Phase Ib/II trial in melanoma. 4SC intends to advance 4SC-202 into a first pivotal study (early 2019) and complete formal development of 4SC-208 with the aim of starting Phase I early 2019. Other ongoing positives include a partnership with Link Health in China for its oncology Eg5 inhibitor, 4SC-205, a worldwide license for 4SC's preclinical inhibitors of the Kv1.3 ion channel, and receipt of a milestone payment from Immunic for the sale of 4SC's immunology portfolio in September 2016.

INDUSTRY OUTLOOK

Resminostat could become the first HDAC inhibitor to gain EU approval for CTCL (vs two HDACs approved in the US). CTCL has been validated as a target indication for HDACs, with vorinostat (Merck & Co) and romidepsin (Celgene) FDA-approved on Phase II data.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	3.3	(7.9)	(8.4)	(58.58)	N/A	N/A
2016	2.1	(10.9)	(10.9)	(54.17)	N/A	N/A
2017e	2.4	(14.5)	(14.5)	(55.74)	N/A	N/A
2018e	2.7	(17.0)	(17.1)	(53.57)	N/A	N/A

Sector: Pharma & healthcare

Price: €1.77
Market cap: €51m
Market: Xetra

Share price graph (€)

Company description

aap Implantate is a German medtech company, focused on developing, manufacturing and selling products for bone fractures. These include the recently launched LOQTEQ trauma plating system, in addition to bone cements.

Price performance

%	1m	3m	12m
Actual	(6.4)	23.7	47.4
Relative*	(4.8)	15.7	25.3

* % Relative to local index

Analyst

Andy Smith

aap Implantate (AAQ)

INVESTMENT SUMMARY

aap is a medical device company concentrated on its core trauma business. aap has recently divested its Biomaterials and contract manufacturing businesses. The geographic focus is now on higher margin established markets like the US, while remaining opportunistic in markets like China and Brazil. The roll-out of the LOQTEQ trauma plates is a key driver and the gold standard in fracture treatment. aap operates largely through a distribution network and global medtech partnerships (eg Zimmer and Smith & Nephew). aap's November 2017 results demonstrated double-digit trauma sales growth in Q3 (€2.9m), and for the first nine months of 2017 (€8m). Sales and EBITDA were also within aap's previously announced guidance. The future for aap's implants are silver-coated to prevent infections.

INDUSTRY OUTLOOK

The changing demographics to older populations in both the developed and developing markets play to greater demands for effective orthopedic devices and specifically the gold standard fracture repair.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2013	N/A	N/A	N/A	N/A	N/A	N/A
2014	N/A	N/A	N/A	N/A	N/A	N/A
2015e	N/A	N/A	N/A	N/A	N/A	N/A
2016e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: 31.5p
Market cap: £67m
Market: AIM

Share price graph (p)

Company description

Abzena provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

Price performance

%	1m	3m	12m
Actual	0.0	(30.0)	(7.4)
Relative*	1.8	(30.4)	(14.2)

* % Relative to local index

Analyst

Andy Smith

Abzena (ABZA)

INVESTMENT SUMMARY

Abzena offers a full-service biologics research and manufacturing capability, enabling safer and more effective biological products, including immunogenicity assessment, protein/antibody engineering, bioconjugation chemistry and biomanufacturing. The fundraising earlier this year of £25m (gross) will enable it to expand its service offering and capacity. The company now aspires to profitability without further equity raises.

Fee-for-services provides stable revenues, while successful commercialization of products created using Abzena's technologies offers the prospect of future royalty revenue; 12 such products are now in the clinic. Abzena has recently announced another licensing deal for its ADC linker technology (ThioBridge™) making for up to ten ADC products, up to three with Halozyme.

INDUSTRY OUTLOOK

The biological services industry is highly competitive but Abzena's deepening portfolio of technologies and services is compelling, while its ADC technology offers safety and efficacy advantages over competitors.

Y/E Mar	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2016	9.9	(6.8)	(7.4)	(5.86)	N/A	N/A
2017	18.7	(7.5)	(8.3)	(5.82)	N/A	N/A
2018e	23.0	(10.0)	(12.3)	(5.54)	N/A	N/A
2019e	34.5	(4.3)	(7.6)	(3.36)	N/A	N/A

Sector: Pharma & healthcare

Price: SEK14.25
Market cap: SEK328m
Market: NASDAQ OMX First North

Share price graph (SEK)

Company description

Acarix, a Swedish company, has developed the CE-marked CADScore to enable about half of the patients to be ruled out from further, expensive testing. Private sales in Germany have started. Full EU sales may start from 2019. US sales might start from 2021.

Price performance

%	1m	3m	12m
Actual	(10.9)	(27.3)	N/A
Relative*	(8.4)	(29.7)	N/A

* % Relative to local index

Analyst

Dr John Savin

Acarix (ACARIX)

INVESTMENT SUMMARY

Acarix sold six CADScore units to 30 Sept with Q2 disposable patch sales of 360 then 520 in Q3 indicating signs of steady device use. Devices always take time to develop a use pattern as clinicians become more familiar with them. Sales to Q3 were SEK 408k with a gross profit of SEK 256k, a 63% margin. The loss was SEK 17m as Q3 expenses rose to fund marketing activities. Cash was SEK 109.5m on 30 Sept after an outflow of SEK 34.3m. The CEO is leaving. The forecast is suspended to enable a sales forecast re-assessment.

INDUSTRY OUTLOOK

CADScore helps doctors to identify cardiac patients who probably require no further risky invasive clinical testing; a published new analysis confirms this. German private healthcare insurance covers about 10% of people and is the immediate target. So far, Germany has accounted for three sales. Major German and EU sales will need public reimbursement probably from late 2019. US marketing will require a US clinical study. The US runs over 3.8m tests per year.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2015	N/A	(15.2)	(15.4)	(114.0)	N/A	N/A
2016	N/A	(26.8)	(26.8)	(183.0)	N/A	N/A
2017e	3.0	(51.8)	(51.4)	(211.0)	N/A	N/A
2018e	3.8	(49.6)	(49.5)	(203.0)	N/A	N/A

Sector: Pharma & healthcare

Price: NZ\$2.49
Market cap: NZ\$242m
Market: NZSX

Share price graph (NZ\$)

Company description

AFT Pharmaceuticals is a speciality pharmaceutical company that operates primarily in Australasia but has product distribution agreements across the globe. The company's product portfolio includes prescription and over-the-counter drugs to treat a range of conditions and a proprietary nebuliser.

Price performance

%	1m	3m	12m
Actual	3.8	(0.4)	(9.8)
Relative*	1.8	(3.7)	(21.2)

* % Relative to local index

Analyst

Maxim Jacobs

AFT Pharmaceuticals (AFT)

INVESTMENT SUMMARY

AFT Pharmaceuticals is a New Zealand-based speciality pharmaceutical company that currently sells 130 prescription speciality generics and OTC products through its own sales force in New Zealand, Australia and South-East Asia and has been expanding its geographic footprint. Maxigesic, its combination acetaminophen/ibuprofen product that is addressing a \$10.4b market, is currently sold and launched in 10 countries and distribution agreements are in place in a total of 124. Additionally, AFT recently reported positive results from a pivotal trial for Maxigesic IV. AFT is also developing a handheld device called SURF Nebuliser, which is able to deliver therapies intranasally, with a main focus on the \$3 billion conscious sedation market.


INDUSTRY OUTLOOK

AFT is a multi product company targeting pharmacy prescription, OTC and hospital markets. Data for Maxigesic offers them a competitive advantage in a fragmented industry.

Y/E Mar	Revenue (NZ\$m)	EBITDA (NZ\$m)	PBT (NZ\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2016	64.0	(7.8)	(10.8)	(11.12)	N/A	N/A
2017	69.2	(15.1)	(18.5)	(19.12)	N/A	N/A
2018e	97.7	1.3	(0.6)	(0.61)	N/A	316.9
2019e	124.2	16.5	14.7	15.10	16.5	18.1

Sector: Pharma & healthcare

Price: NIS1.22
Market cap: NIS80m
Market: TASE

Share price graph (NIS)

Company description

Allium Medical Solutions is a company focused on developing and marketing minimally invasive devices in various areas: cardiovascular, metabolic, genitourinary and gastrointestinal. The company has three selling product lines: Allium Stents, IBI (EndoFast) and Gardia Medical.

Price performance

%	1m	3m	12m
Actual	6.4	26.0	0.2
Relative*	4.6	20.1	(4.0)

* % Relative to local index

Analyst

Juan Pedro Serrate

Allium Medical (ALMD)

INVESTMENT SUMMARY

Allium Medical Solutions is a company focused on developing and marketing minimally invasive devices in various areas: cardiovascular, metabolic, genitourinary and gastrointestinal. The company has three selling product lines: Allium Stents, IBI (EndoFast) and Gardia Medical. Peripheral stents and EndoFast urogynecology devices generate the bulk of revenues (70% of NIS7.3m in 2016). Allium has achieved revenue CAGR of 23% in 2011-16. The investment case rests on Allium's ability to execute on its ambitious growth strategy, with revenues expanding at a double-digit rate as the company continues to gain market share in established and new regions. Cash equivalents and short-term deposits at end June 2017 plus proceeds of July 2017 equity raise were NIS25.6m.

INDUSTRY OUTLOOK

We expect Allium's growth to accelerate in the medium term, driven by new markets, resulting in 2016-20e revenue CAGR of 46%. Allium also has two devices in preclinical development: Allevetix for diabetes and obesity (start a clinical trial in 2017) and TruLeaf, a mitral valve replacement device that will develop until completion of clinical trial. Gardia Medical's Wirion device is approaching FDA submission, approval in the US is important for strategic partnering discussions.

Y/E Dec	Revenue (NISm)	EBITDA (NISm)	PBT (NISm)	EPS (NIS)	P/E (x)	P/CF (x)
2015	5.2	(16.3)	(18.5)	(0.65)	N/A	N/A
2016	7.4	(20.4)	(22.0)	(0.49)	N/A	N/A
2017e	9.7	(19.5)	(20.3)	(0.35)	N/A	N/A
2018e	16.6	(6.8)	(7.3)	(0.11)	N/A	N/A

Sector: Pharma & healthcare

Price: 52.5p
Market cap: £61m
Market: AIM

Share price graph (p)

Company description

Angle is a world leading liquid biopsy company with a potentially disruptive platform technology. The patented Parsortix cell separation platform can harvest circulating tumour cells and other very rare cells from a blood sample for downstream analysis.

Price performance

%	1m	3m	12m
Actual	12.9	61.5	(11.8)
Relative*	15.0	60.7	(18.3)

* % Relative to local index

Analyst

Dr Jonas Peciuslis

Angle (AGL)

INVESTMENT SUMMARY

Angle's Parsortix cell separation platform is used to detect and harvest circulating tumour cells (CTCs) from blood. CTCs provide the complete picture since viable, intact CTCs can be used for DNA, RNA and protein analysis as well as culturing and xenograft models. Recently, Angle acquired certain assets of Axela, a multiplex tools company providing enhanced analysis of protein, DNA and RNA. This will allow Angle to offer a "sample to answer" solution to its clients. The company reported initial results from its two lead clinical studies (n=200 each) for triaging women with ovarian masses before surgery. Reported sensitivity was up to 95%, while specificity was significantly higher than existing tests. Recently the company has partnered with Philips to develop liquid biopsy solutions and established co-marketing agreement with Qiagen. Another key catalyst is the completion of the FDA clinical studies in breast cancer expected in H118, which is a part of the approval process in the US. We are updating our estimates.

INDUSTRY OUTLOOK

The precision medicine approach is an initiative aiming to improve treatment efficacy by tailoring the treatment to the patient and their disease with liquid biopsy being one of the key enabling tools.

Y/E Apr	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2016	0.4	(4.9)	(5.0)	(7.97)	N/A	N/A
2017	0.5	(6.7)	(6.9)	(8.03)	N/A	N/A
2018e	N/A	N/A	N/A	N/A	N/A	N/A
2019e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: 189.5p
Market cap: £182m
Market: LSE

Share price graph (p)

Company description

Arix Bioscience is a life sciences portfolio company specialising in therapeutic and diagnostic companies. The portfolio currently includes direct and indirect investments across the life sciences.

Price performance

%	1m	3m	12m
Actual	(1.0)	(5.3)	N/A
Relative*	0.8	(5.7)	N/A

* % Relative to local index

Analyst

Maxim Jacobs

Arix Bioscience (ARIX)

INVESTMENT SUMMARY

Arix is a new transatlantic life sciences portfolio company drawing from managerial expertise at all levels of the pharma industry to engage in opportunities ranging from seed investing to public equity. It draws on a network of deal sources established through agreements with academia, life science accelerators, other funds, and through partnerships with big pharma. The portfolio currently includes a number of direct investments (Depixus, Artios, OptiKira, Autolus, Verona, Iterum, Harpoon, Mitoconix, LogicBio PreciThera, Amplyx and Atox), and Arix is taking an active role in the operations of these companies with board positions in each.

INDUSTRY OUTLOOK

Biopharma venture investing has historically outperformed the broader market, and Arix's permanent capital model allows it to capitalize on these opportunities without being bound to specific exit timing.

Y/E Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2015	N/A	N/A	N/A	N/A	N/A	N/A
2016	0.0	(2.2)	(2.2)	(21.52)	N/A	N/A
2017e	5.3	(5.1)	(4.5)	(4.68)	N/A	N/A
2018e	2.1	(6.0)	(0.5)	(0.49)	N/A	N/A

Sector: Pharma & healthcare

Price: NTD33.05
Market cap: NTD4301m
Market: Taiwan

Share price graph (NTD)

Company description

ASLAN Pharmaceuticals is a Singapore based drug developer targeting Asia prevalent diseases. Varlitinib is in pivotal clinical trials for biliary tract cancer and gastric cancer and ASLAN003 will be advanced to Phase II trials for acute myeloid leukaemia.

Price performance

%	1m	3m	12m
Actual	(15.0)	(12.5)	N/A
Relative*	(11.6)	(10.7)	N/A

* % Relative to local index

Analyst

Dr Nathaniel Calloway

ASLAN Pharmaceuticals (6497)

INVESTMENT SUMMARY

ASLAN is a pharmaceutical company focused on in-licensing early-stage assets for diseases with a high prevalence in Asia that are orphans in the West. This allows the company to quickly progress these assets through clinical trials in Asia. The goal then is to out-license rights to the EU and Japan while commercialising in the US and other Asian geographies. The company's lead programme is varlitinib, a pan-HER inhibitor in a pivotal trial for biliary tract cancer (BTC) and Phase II/III for gastric cancer (GC). Initial readouts for these trials are planned for 2018. It also has an ongoing Phase II clinical trial of ASLAN003, an inhibitor of dihydroorotate dehydrogenase, which is being tested for acute myeloid leukaemia, a novel indication for this class of drug.

INDUSTRY OUTLOOK

ASLAN's Asia focused development strategy allows it to address certain indications that have otherwise proven difficult to develop drugs for, such as biliary tract cancer, which has no approved targeted therapies.

Y/E Dec	Revenue (NTDm)	EBITDA (NTDm)	PBT (NTDm)	EPS (fd) (NTD)	P/E (x)	P/CF (x)
2015	0.0	(384.5)	(402.7)	(7.32)	N/A	N/A
2016	373.0	(232.7)	(246.5)	(2.35)	N/A	N/A
2017e	0.0	(1082.0)	(1092.8)	(8.81)	N/A	N/A
2018e	0.0	(1097.9)	(1109.0)	(8.52)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$0.30
Market cap: US\$4m
Market: NASDAQ

Share price graph (US\$)

Company description

Based in Seattle, WA, Atossa Genetics is focused on the development of locally administered pharmaceuticals for the treatment of pre-cancer and early-stage breast cancer. Lead candidate afimoxigene topical gel is expected to start a Phase II study in 2016 in breast hyperplasia or DCIS.

Price performance

%	1m	3m	12m
Actual	(22.3)	(35.7)	(83.0)
Relative*	(23.9)	(40.4)	(85.6)

* % Relative to local index

Analyst

Pooya Hemami

Atossa Genetics (ATOS)

INVESTMENT SUMMARY

Atossa is advancing endoxifen, a metabolite of tamoxifen, as a topical treatment for high mammographic breast density (MBD), a condition associated with higher cancer risk. It recently reported positive Phase I safety data for both formulations. Atossa is also developing oral endoxifen as well as a potential treatment for breast cancer patients refractory to tamoxifen. About 20-25% of the 1.0m women taking tamoxifen worldwide develop resistance to it, and have an increased risk for cancer recurrence. Atossa is also advancing its proprietary intraductal microcatheter (IDMC), intended to selectively introduce drugs to breast ducts to improve drug targeting. It is combining its IDMC with established cancer drug fulvestrant and started a Phase II trial in 2016.


INDUSTRY OUTLOOK

Atossa's programs may fall under the 505(b)2 development pathway, which would reduce the breadth of data needed to support a marketing application. The firm plans to start Phase II trials for oral and topical endoxifen in Q118. Atossa had \$2.8 net cash at Q317, and raised \$5.5m in an equity offering in Q417, which we estimate extends its runway into mid-2018.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2015	0.0	(9.5)	(9.8)	(514.81)	N/A	N/A
2016	0.0	(6.9)	(7.2)	(245.98)	N/A	N/A
2017e	0.0	(7.7)	(7.8)	(82.72)	N/A	N/A
2018e	0.0	(11.4)	(11.5)	(43.40)	N/A	N/A

Sector: Pharma & healthcare

Price: CHF75.90
Market cap: CHF901m
Market: Swiss Stock Exchange

Share price graph (CHF)

Company description

Basilea focuses on anti-infectives and oncology. Lead products are Cresemba (an antifungal), which is approved in the US and Europe, and Zevtera (an anti-MRSA broad-spectrum antibiotic), approved in many European and non-European countries for pneumonia.

Price performance

%	1m	3m	12m
Actual	(3.3)	(6.2)	9.4
Relative*	(3.9)	(10.3)	(6.7)

* % Relative to local index

Analyst

Dr Susie Jana

Basilea Pharmaceutica (BSLN)

INVESTMENT SUMMARY

Basilea has two approved hospital-based products: Cresemba (severe mold infections) and Zevtera (bacterial infections). Zevtera should enter US phase III development in the next 3-6 months following agreement of the SPA with the FDA and the award of a BARDA contract (worth up to \$108m). Multiple licensing/distribution agreements announced in 2017 for launched assets Cresemba and Zevtera should drive top-line growth faster than we had expected. Major deals include; Cresemba in Europe (ex Nordics), Russia, Turkey, Israel, China and Asia Pacific with Pfizer, Zevtera in China with CR Gosun, and in Europe with Cardiome. Basilea's earlier-stage oncology pipeline focuses on drugs that target resistance to current cancer therapies. BAL101553 is being developed as a tumor checkpoint controller (final phase I/IIa data at was presented at ASCO). BAL3833, a panRAF kinase inhibitor, is in Phase I development.


INDUSTRY OUTLOOK

There is an increasing need for novel antimicrobial agents with efficacy against resistant strains of bacteria (eg MRSA), and/or improved side effect profiles. Hence the opportunities for Zevtera and Cresemba could be significant.

Y/E Dec	Revenue (CHFm)	EBITDA (CHFm)	PBT (CHFm)	EPS (fd) (CHFc)	P/E (x)	P/CF (x)
2015	52.8	(58.9)	(61.3)	(607.22)	N/A	N/A
2016	66.0	(41.6)	(50.9)	(505.74)	N/A	N/A
2017e	95.1	(12.1)	(19.8)	(183.23)	N/A	79.6
2018e	84.4	(20.2)	(28.0)	(259.44)	N/A	N/A

Sector: Pharma & healthcare

Price: NIS14.73
Market cap: NIS54m
Market: TASE

Share price graph (NIS)

Company description

Based in Israel, BioLight is an emerging ophthalmic company focused on the development and commercialisation of products and product candidates that address ocular conditions. Lead products IOPTiMate and VS-101 are directed towards the treatment of glaucoma.

Price performance

%	1m	3m	12m
Actual	11.2	0.1	50.7
Relative*	9.4	(4.6)	44.4

* % Relative to local index

Analyst

Pooya Hemami

Bio-Light Life Sciences (BOLT)

INVESTMENT SUMMARY

BioLight Life Sciences developing Eye-D VS-101, an extended-dose latanoprost drug implant designed to treat glaucoma that recently reported positive data in a Phase I/IIa trial, and TeaRx, a dry eye syndrome diagnostic test. VS-101 can be helpful for the 20-60% of glaucoma patients who do not comply with daily eye drop therapy. BioLight's H117 net cash position of NIS25.5m (with NIS13.5m held at the parent company and the remainder at its subsidiaries) should be sufficient for the company to maintain operations through Q417.


INDUSTRY OUTLOOK

BioLight's IOPTiMate subsidiary (of which it holds a 70% stake) signed a definitive agreement in November 2017 to be acquired by Chengdu Kanghong Pharma. The transaction consists of four stages, with the initial stage consisting of a \$7m investment in IOPTiMate for a 19% stake. The subsequent stages involve the acquisition of the remaining IOPTiMate shares from all its other shareholders (including BioLight), and are subject to the fulfillment of several conditions, including meeting IOPTiMate operational objectives and the renewal of Chinese registration by April 2018 for its IOPTiMate laser surgical device (for the treatment of glaucoma). If all conditions are met and if the transaction is fully executed (by mid-2021), the gross consideration to BioLight is expected to range between about \$23m and \$27.5m.

Y/E Dec	Revenue (NISm)	EBITDA (NISm)	PBT (NISm)	EPS (NIS)	P/E (x)	P/CF (x)
2015	1.4	(24.3)	(25.1)	(6.96)	N/A	N/A
2016	2.1	(20.2)	(26.3)	(5.55)	N/A	N/A
2017e	2.2	(27.2)	(30.1)	(6.88)	N/A	N/A
2018e	3.6	(25.7)	(27.9)	(7.50)	N/A	N/A

Sector: Pharma & healthcare

Price: NIS0.46
Market cap: NIS121m
Market: TASE

Share price graph (NIS)

Company description

BiondVax is developing a potentially universal influenza vaccine named M-001 that could be positioned as a primer for seasonal or pandemic vaccines or as a standalone influenza vaccine. So far M-001 has been tested in two Phase I/II and four Phase II trials and consistently demonstrated safety and immunogenicity to multiple flu virus strains.

Price performance

%	1m	3m	12m
Actual	(20.4)	(33.2)	31.2
Relative*	(21.7)	(36.3)	25.6

* % Relative to local index

Analyst

Dr Jonas Pecilius

BiondVax Pharmaceuticals (BVXV)

INVESTMENT SUMMARY

BiondVax with its epitope-based multimeric vaccine candidate M-001 is among the leaders in the development of the universal influenza vaccine worldwide. Recently, the company announced an agreement with the US National Institutes of Health (NIH) for a Phase II trial, which will be funded by the NIH and be the first ever trial in the US with M-001. In July 2017, the company announced positive Phase IIb trial results with both primary endpoints achieved (safety and influenza-specific cellular immune responses). Before that M-001 was tested in two Phase I/II and three Phase II trials involving 479 participants in total and was shown to be consistently safe and immunogenic, and demonstrated synergy with conventional flu vaccines. BiondVax had cash of \$22.1m (NIS78.1m) at end-Q317 and also has access to €20m from the European Investment Bank. This will support the development of M-001 into Phase III.

INDUSTRY OUTLOOK

Current influenza vaccines are solely strain specific, needs to be updated every year with the effectiveness still lingering around 40%. There is a clear need for a more reliable vaccine that is both more immunoprotective and with coverage against a wider range of flu strains for the entire population and in particular for the elderly.

Y/E Dec	Revenue (NISm)	EBITDA (NISm)	PBT (NISm)	EPS (NIS)	P/E (x)	P/CF (x)
2015	0.0	(10.7)	(10.2)	(0.10)	N/A	N/A
2016	0.0	(11.3)	(9.2)	(0.07)	N/A	N/A
2017e	0.0	(14.5)	(15.0)	(0.08)	N/A	N/A
2018e	0.0	(18.6)	(19.7)	(0.08)	N/A	N/A

Sector: Pharma & healthcare

Price: €24.70
Market cap: €256m
Market: Euronext Growth

Share price graph (€)

Company description

Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. The development process combines the expertise of a wide range of technical and medical experts.

Price performance

%	1m	3m	12m
Actual	2.1	(0.2)	(23.3)
Relative*	3.3	(5.1)	(33.6)

* % Relative to local index

Analyst

Pooya Hemami

Carmat (ALCAR)

INVESTMENT SUMMARY

Carmat obtained approval in May 2017 from the French regulatory agency (ANSM) to resume its pivotal trial for the Carmat heart. Carmat is now working to expand access in the 20-25-patient study to other countries (recently sites in Czech Republic and Kazakhstan was added). It is also preparing a new and more automated production facility, to be ready in early 2018. Carmat recently announced an €46m equity financing (up to €52.9m if all over-allotments are exercised), to be completed in mid-December 2017, and with the majority of proceeds to be used towards the ongoing EU pivotal trial. Upon completion of the financing, given the firm's 30 June 2017 net cash position of €19.9m, we estimate Carmat can finance operations into Q219.


INDUSTRY OUTLOOK

The Carmat artificial heart is being developed as a permanent replacement or destination therapy (DT) for chronic biventricular heart failure or acute myocardial infarction patients, who do not have access to a human donor heart. Despite the high EU and US prevalence of Stage IV heart failure (c 500,000 patients), the shortfall in donor hearts is such that only about 3,800 human heart transplants were performed in Europe and the US in 2013.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	0.0	(19.4)	(20.6)	(381.32)	N/A	N/A
2016	0.3	(24.1)	(25.7)	(379.73)	N/A	N/A
2017e	0.0	(22.0)	(22.1)	(367.12)	N/A	N/A
2018e	0.0	(24.7)	(26.3)	(435.57)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$10.90
Market cap: US\$153m
Market: NASDAQ

Share price graph (US\$)

Company description

Cellular Biomedicine Group is a biotechnology company developing cell-based therapeutics with operations primarily in China. It has completed Phase II clinical trials of ReJoin, an autologous progenitor cell therapy for osteoarthritis, and it is developing a similar allogeneic product (AlloJoin). It has developed a CD19 CAR-T, which is currently in Phase I testing in China.

Price performance

%	1m	3m	12m
Actual	5.8	(1.4)	(18.4)
Relative*	3.5	(8.4)	(30.8)

* % Relative to local index

Analyst

Dr Nathaniel Calloway

Cellular Biomedicine Group (CBMG)

INVESTMENT SUMMARY

Cellular Biomedicine Group (CBMG) is a trans-Pacific cell therapy company developing products in China and the US. It has two ongoing Phase I clinical trials of CD19 chimeric antigen receptor T-cell (CAR-T) therapies for blood cancers (adult ALL and DLBCL) in China with data expected around year-end 2017. Additionally, it is adapting its knee osteoarthritis (KOA) treatment ReJoin as an allogeneic product, AlloJoin, which it hopes to develop in the US after a 2017 or 2018 IND.


INDUSTRY OUTLOOK

The company is focusing on CAR-T. The first CAR-T therapy (Kymriah from Novartis) was just recently approved in August 2017 for the treatment of pediatric and young adult patients with ALL at a price of \$475,000 per treatment. Kite Pharmaceuticals also has a pending application for approval of its CD19 CAR-T therapy (for the treatment of DLBCL) with an FDA decision expected before 29 November 2017. Gilead announced the intent to acquire Kite and its CAR-T programs for \$12bn in August 2017.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2015	2.5	(11.0)	(12.5)	(108.61)	N/A	N/A
2016	0.6	(15.7)	(18.1)	(134.30)	N/A	N/A
2017e	0.2	(16.2)	(18.8)	(138.43)	N/A	N/A
2018e	0.0	(17.9)	(17.8)	(124.98)	N/A	N/A

Sector: Pharma & healthcare

Price: €32.23
Market cap: €318m
Market: Euronext Brussels

Share price graph (€)

Company description

Celyad is developing an innovative Natural Killer Receptor CAR T-cell therapy (CYAD-01). This targets targets five solid and two hematologic cancers in the THINK study. A colorectal cancer study with chemotherapy (SHRINK) is underway.

Price performance

%	1m	3m	12m
Actual	(32.3)	(26.7)	80.1
Relative*	(31.3)	(28.3)	59.5

* % Relative to local index

Analyst

Dr John Savin

Celyad (CYAD)

INVESTMENT SUMMARY

Celyad has seen a near complete response with "clinical validity" in an AML patient treated with CYAD-01 NKR CAR T-cell therapy at the lowest dose in the THINK trial. As two stable disease cases in colorectal cancer have also been seen, Celyad will start to further develop AML and colorectal cancers as initial leads after completing the THINK dose escalation stage. CYAD-01 does not use preconditioning but combination approaches will now be explored. The SHRINK trial is underway in mCRC directly after FOLFOX therapy is approved to start in Belgium. Cash on 30 Sept was €40m due to last into H1 2019.


INDUSTRY OUTLOOK

The CYAD-01 near complete response in AML, an intractable cancer, is a major milestone showing that NKR CAR therapy is an alternative to standard CAR-T. Celyad's NKR CAR T-cells target ubiquitous "stress" cancer antigens. Celyad has a leading IP position in allogeneic therapy and a Novartis deal. Two US CAR T-cell therapies are approved and Novartis has filed in the EU so the market will develop over 2018.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	0.0	(27.8)	(27.6)	(317.0)	N/A	N/A
2016	8.5	(24.1)	(22.8)	(209.0)	N/A	N/A
2017e	8.3	(26.7)	(27.2)	(286.0)	N/A	N/A
2018e	9.0	(24.7)	(25.2)	(265.0)	N/A	N/A

Sector: Pharma & healthcare

Price: NIS0.55
Market cap: NIS81m
Market: TASE

Share price graph (NIS)

Company description

CollPlant is an Israel-based regenerative medicine company. It is focused on developing and commercializing tissue repair products with its plant-based technology, rhCollagen. It has two products on the market, VergenixSTR and Vergenix FG, and has received several orders for its 3D bioprinting product bioInk.

Price performance

%	1m	3m	12m
Actual	18.9	37.9	35.5
Relative*	17.0	31.5	29.8

* % Relative to local index

Analyst

Maxim Jacobs

CollPlant Holdings (CLPT)

INVESTMENT SUMMARY

CollPlant is an Israel-based regenerative medicine company. It is focused on developing and commercialising tissue repair products with its plant-based technology, rhCollagen. It has two products on the market, VergenixSTR and VergenixFG, and has received several orders for its 3D bioprinting product bioInk. It received its first order in September from a major biotechnology company, which subsequently reordered more product valued in the hundreds of thousands of dollars. The company intends to use the product to print organs for transplant. Additionally, CollPlant has received an order from a major medical device company in the order of multiple tens of thousands of dollars to develop a 3D printed orthopaedic implant.

INDUSTRY OUTLOOK

Orthobiologics and advanced wound care are substantial growing markets and are estimated to be worth \$6.7bn (according to GlobalData) and \$8.5bn (according to Smith & Nephew) respectively.

Y/E Dec	Revenue (NISm)	EBITDA (NISm)	PBT (NISm)	EPS (NIS)	P/E (x)	P/CF (x)
2015	0.0	(18.0)	(18.7)	(22.03)	N/A	N/A
2016	0.3	(27.0)	(27.9)	(27.72)	N/A	N/A
2017e	1.6	(19.2)	(20.6)	(15.47)	N/A	N/A
2018e	3.2	(16.5)	(17.5)	(9.66)	N/A	N/A

Sector: Pharma & healthcare

Price: €4.04
Market cap: €36m
Market: Euronext Paris

Share price graph (€)

Company description

Crossject develops new therapeutic entities to be administered using its proprietary, needle-free injection system, ZENEO. Crossject has seven products in its development pipeline, including products for rheumatoid arthritis, anaphylactic shock, migraine and Parkinson's.

Price performance

%	1m	3m	12m
Actual	(10.6)	(23.8)	(9.7)
Relative*	(9.5)	(27.5)	(21.7)

* % Relative to local index

Analyst

Maxim Jacobs

Crossject (ALCJ)

INVESTMENT SUMMARY

Crossject has developed a deep pipeline of products that are based on its proprietary needle-free injection system, ZENEO, across a variety of indications. The benefits of ZENEO include no need for needles, as well as a simple and quick (~1/10th of a second) delivery of the drug. Its first commercial product, ZENEO Sumatriptan for the acute treatment of migraines, should reach the market in 2020 and US partner is expected to be signed by the end of the year. The next products to reach the market include ZENEO Midazolam and ZENEO Adrenaline for epilepsy and anaphylactic shock, respectively. They should reach the market in 2020.


INDUSTRY OUTLOOK

Traditional injections have multiple issues with them which inhibit patient acceptance. These often include: lack of convenience, a multi-step injection process, difficulty in performing the injection correctly, and difficulty delivering the injection to the right tissue, particularly for overweight patients.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	2.4	(5.5)	(6.7)	(85.33)	N/A	N/A
2016	1.4	(5.6)	(7.3)	(85.19)	N/A	N/A
2017e	2.9	(6.8)	(8.8)	(74.91)	N/A	N/A
2018e	0.0	(11.0)	(12.0)	(103.05)	N/A	N/A

Sector: Pharma & healthcare

Price: 9.1p
Market cap: £25m
Market: AIM

Share price graph (p)

Company description

e-Therapeutics is a UK-based drug discovery company that has developed a proprietary network-driven drug discovery platform. Following a strategic review by the new CEO, the focus is now on commercialisation: securing partners for its platform, discovery and development projects.

Price performance

%	1m	3m	12m
Actual	(4.0)	(15.1)	9.0
Relative*	(2.2)	(15.5)	0.9

* % Relative to local index

Analyst

Dr Charlotte Hetzel

e-Therapeutics (ETX)

INVESTMENT SUMMARY

e-Therapeutics (ETX) offers public market investors a unique opportunity to gain exposure to a proprietary, cutting-edge in silico drug discovery platform that has already attracted significant investment and has been fully operational since 2014. This second-generation platform has generated new chemical entities (NCEs) in several different disease areas and, under a new CEO, is on the cusp of commercial validation. The priority for the company is securing deals to provide external validation of this approach. ETX's strength is its discovery capability, particularly in complex disease; it also has two internal discovery projects with the prospect of more to come.


INDUSTRY OUTLOOK

Network-driven approaches could potentially revolutionise drug discovery and shorten the path to market by minimising technical risks and drug development costs. ETX is differentiated from its competitors through its expertise in curating, processing and analysing data in the context of mechanistic modelling of disease.

Y/E Jan	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2016	0.0	(11.3)	(11.1)	(3.3)	N/A	N/A
2017	0.0	(13.5)	(13.4)	(3.9)	N/A	N/A
2018e	0.0	(7.7)	(7.7)	(2.3)	N/A	N/A
2019e	0.0	(7.2)	(7.2)	(2.1)	N/A	N/A

Sector: Pharma & healthcare

Price: €1.68
Market cap: €131m
Market: Euronext Paris

Share price graph (€)

Company description

Genkyotex and privately-held company Gentecel have signed a contribution agreement to form a combined entity focused on the development of NOX inhibitors for fibrosis and other indications. The transaction has been approved by Gentecel's shareholders.

Price performance

%	1m	3m	12m
Actual	(7.2)	(3.4)	(36.4)
Relative*	(6.1)	(8.1)	(44.9)

* % Relative to local index

Analyst

Juan Pedro Serrate

Genkyotex (GKTX)

INVESTMENT SUMMARY

Genkyotex is a biotech company focused on NOX science and the development of small molecule NOX inhibitors for fibrosis and inflammation. Lead product GKT831 is in a Phase II clinical trial in primary biliary cholangitis (PBC) with data in 2018. Second product GKT771 is in advanced preclinical stage and will be Phase I ready by end 2017 and focus on inflammation and angiogenesis. A Phase II investigator-sponsored trial in patients with Type 1 diabetes (T1D) and kidney disease will start in Australia by end-2017. The company also has a portfolio of early stage NOX inhibitors for oncology, hearing loss and neurology indications. Genkyotex has partnership with the Serum Institute of India Ltd (SIIL) which involves up to \$57m of milestone payments and single-digit royalties on net sales. Cash and equivalents were €15.3m at 30 September 2017, sufficient until 2018.

INDUSTRY OUTLOOK

The new company is focused on NOX science, an enzyme complex that generates reactive oxygen species (ROS). Increased NOX activity has been linked to various diseases; in particular to metabolic and cardiovascular diseases and neurodegeneration.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	N/A	N/A	N/A	N/A	N/A	N/A
2015	N/A	N/A	N/A	N/A	N/A	N/A
2016e	1.3	(21.7)	(21.7)	(27.8)	N/A	N/A
2017e	0.0	(12.0)	(12.0)	(15.4)	N/A	N/A

Sector: Pharma & healthcare

Price: 4947.5p
Market cap: £3287m
Market: AIM, NASDAQ

Share price graph (p)

Company description

Hutchison China MediTech (HCM) is an innovative China-based biopharma company targeting the global market for novel, highly selective oral oncology and immunology drugs. Its established China Healthcare business is growing ahead of the market. HCM is the healthcare arm of CK Hutchison (c 40% listed on AIM and NASDAQ).

Price performance

%	1m	3m	12m
Actual	9.0	31.4	116.5
Relative*	11.0	30.8	100.5

* % Relative to local index

Analyst

Dr Susie Jana

Hutchison China MediTech (HCM)

INVESTMENT SUMMARY

HCM has built a substantial pipeline of potential first-in-class or best-in-class tyrosine kinase inhibitor (TKI) drugs, some of which are in development with strategic partners. HCM have submitted a new drug application (partnered with Eli Lilly) for fruquintinib in CRC to the China FDA (full Phase III CRC data [China] was presented at ASCO 2017), marking a major milestone in the company's life. Separately in collaboration with AstraZeneca, HCM have initiated SAVOIR, a global Phase III trial of savolitinib in PRCC. Our forecasts and valuation have been placed under review.

INDUSTRY OUTLOOK

HCM's profitable Chinese healthcare business continues to benefit from the fast-growing domestic market, while the clinical, regulatory and technological environments are highly conducive to novel drug development. In the longer term, if the oncology and immunology pipeline comes to fruition, HCM has the potential to become a global oncology and immunology player.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2015	178.2	(7.8)	(10.5)	14.6	447.4	N/A
2016	216.1	(44.3)	(47.4)	19.6	333.3	N/A
2017e	N/A	N/A	N/A	N/A	N/A	N/A
2018e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: €0.59
Market cap: €28m
Market: Euronext Growth

Share price graph (€)

Company description

Hybrigenics is a French biotech company. It provides protein-protein and small molecule analysis services and is conducting anti-cancer studies on lead drug inecalcitol, primarily in adult leukaemias.

Price performance

%	1m	3m	12m
Actual	5.4	1.7	(30.7)
Relative*	6.6	(3.2)	(39.9)

* % Relative to local index

Analyst

Juan Pedro Serrate

Hybrigenics (ALHYG)

INVESTMENT SUMMARY

Hybrigenics has adopted a development strategy with vitamin D3 derivative inecalcitol, focusing on adult haematological cancers. In addition to chronic lymphocytic leukaemia (CLL) and chronic myeloid leukaemia (CML), Hybrigenics is prioritising acute myeloid leukaemia (AML) given inecalcitol's orphan status in the US and Europe and the scarcity of treatment options in this aggressive and difficult to treat leukaemia. Inecalcitol has the potential to enhance rather than replace approved therapies, particularly with its benign safety profile. The company has refocused exclusively on R&D after the MBO of its subsidiary dedicated to proteomic services. Net cash at end July 2017 was €11m.


INDUSTRY OUTLOOK

An international Phase II study in AML started in France and the US in H216. Encouraging initial data from a Phase II in CML has been presented. At interim, 33% of patients who had completed one year in the study achieved a deep molecular response (DMR) which may allow patients to discontinue treatment (functional cure). Both trials will be expanded to other countries and combinations with other kinase inhibitors, respectively. Finally, the collaboration with Servier on ubiquitin-specific proteases is ongoing and the company received a milestone payment of €1.5m during H116.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	2.2	(4.4)	(5.0)	(14.6)	N/A	N/A
2016	3.6	(3.8)	(4.3)	(12.0)	N/A	N/A
2017e	2.5	(7.8)	(8.0)	(19.5)	N/A	N/A
2018e	5.5	(5.1)	(5.4)	(11.6)	N/A	N/A

Sector: Pharma & healthcare

Price: SEK89.00
Market cap: SEK1541m
Market: NASDAQ OMX First North

Share price graph (SEK)

Company description

Immunovia is a Swedish company, specialised in diagnostics for oncology and autoimmune diseases. Its main product is IMMray PanCan-d, an antibody microarray based on its proprietary IMMray platform. A prospective trial in high-risk patients will start in Q416. The company expects to generate initial out-of-pocket sales in 2018.

Price performance

%	1m	3m	12m
Actual	(9.6)	(17.2)	5.0
Relative*	(7.1)	(19.9)	(3.4)

* % Relative to local index

Analyst

Juan Pedro Serrate

Immunovia (IMMUNOV)

INVESTMENT SUMMARY

Immunovia is developing IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. Early diagnosis could improve 5-year survival rate to c 50%. On the back of positive retrospective data (PanCan-d discriminated healthy individuals from those with pancreatic cancer with 96% accuracy) Immunovia started a prospective trial in high-risk patients in Dec 2016. The company expects to generate initial out-of-pocket sales in 2018. It has signed a collaboration with the US National Cancer Institute to validate biomarkers in patients over 50 years old with new onset diabetes. Additionally, IMMray biomarker signatures distinguished Systemic Lupus Erythematosus (SLE) from three other autoimmune diseases with 96% accuracy; and Rheumatoid Arthritis (RA) from SLE, Sjögren Syndrome and Systemic Vasculitis, with 89% accuracy. Cash and equivalents at 30 September 2017 were SEK215.3m.

INDUSTRY OUTLOOK

Immunovia is targeting a potential opportunity of over SEK36bn. It will first target patients with a family history of pancreatic cancer, or other pancreatic diseases with increased risk of cancer (estimated at 200,000 in the EU/US) followed by patients over 50 years of age diagnosed with type 2 diabetes, (estimated at 3.4 million new patients per year).

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2015	17.0	(7.1)	(7.4)	(65.0)	N/A	N/A
2016	24.5	(14.4)	(14.7)	(98.0)	N/A	N/A
2017e	27.8	(17.8)	(17.6)	(104.0)	N/A	N/A
2018e	43.6	(30.3)	(30.8)	(183.0)	N/A	N/A

Sector: Pharma & healthcare

Price: A\$0.02
Market cap: A\$57m
Market: ASX

Share price graph (A\$)

Company description

Immutep was formerly known as Prima Biomed. Its pipeline is based on three LAG-3 products: efitlagimod alpha (IMP321) for cancer chemo-immunotherapy and immunotherapy-immunotherapy combinations, and partnered products IMP731 (GSK), IMP701 (Novartis) and IMP761.

Price performance

%	1m	3m	12m
Actual	(14.3)	14.3	(33.3)
Relative*	(14.1)	7.9	(38.6)

* % Relative to local index

Analyst

Dr Dennis Hulme

Immutep (IMM)

INVESTMENT SUMMARY

Immutep (formerly Prima BioMed) has three promising clinical assets based on a versatile immunotherapy target Lymphocyte activation gene-3, LAG-3 (one partnered with GSK and a second partnered with Novartis). The lead in-house LAG-3 product, efitlagimod alpha (IMP321), is being developed initially in metastatic breast cancer in combination with chemotherapy (226-patient randomised Phase IIb underway, 47% response rate in the 15-patient dose-escalation phase) and in melanoma in combination with the anti-PD1 checkpoint inhibitor Keytruda (Phase I currently recruiting final cohort, 33% preliminary response rate in first two cohorts). Novartis and GSK are progressing clinical trials of partnered LAG-3 programmes, providing additional validation for the technology. Prima's pipeline also includes IMP761, a first-in-class LAG-3 agonist antibody in preclinical development which could potentially help treat autoimmune diseases.

INDUSTRY OUTLOOK

Immunotherapies are among the most promising class of products for cancer and autoimmune diseases. The LAG-3 products are potentially first-in-class, each with distinct mechanisms and applications.

Y/E Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	1.9	(12.1)	(13.7)	(0.6)	N/A	N/A
2017	4.1	(7.8)	(8.4)	(0.4)	N/A	N/A
2018e	3.5	(8.7)	(8.4)	(0.4)	N/A	N/A
2019e	10.5	(0.3)	0.0	0.0	N/A	N/A

Sector: Pharma & healthcare

Price: NIS18.72
Market cap: NIS488m
Market: TASE

Share price graph (NIS)

Company description

Intec Pharma is a drug delivery company that has developed the accordion pill, a novel gastroretentive controlled release formulation. The company is currently using this technology to develop AP-CDLD for Parkinson's in Phase III and AP-ZP for insomnia in Phase II.

Price performance

%	1m	3m	12m
Actual	(28.1)	(26.4)	(5.9)
Relative*	(29.3)	(29.9)	(9.9)

* % Relative to local index

Analyst

Maxim Jacobs

Intec Pharma (NTEC)

INVESTMENT SUMMARY

Intec Pharma is a drug delivery company that has developed a novel drug delivery device termed the accordion pill (AP), a folded, multilayer membrane packaged into a normal capsule, which expands to a sheet within the stomach to many times its original size. This property causes the pill to be retained in the stomach for up to 12 hours. This is ideal for drugs with local activity in the stomach or upper digestive tract or with poor solubility. AP-CDLD, a controlled release formulation of carbidopa and levodopa for Parkinson's is in Phase III with enrollment expected to complete by Q318 with data in H219. They have also completed a Phase I trial of AP-CBD/THC, their cannabinoid program and will be making some design changes to improve the PK.

INDUSTRY OUTLOOK

Parkinson's disease is a neurodegenerative disease in which the dopamine secreting neurons in the brain are lost, leading to severe motor defects and cognitive impairment. Approximately one million people in the US have Parkinson's.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2015	0.0	(8.3)	(7.2)	(92.16)	N/A	N/A
2016	0.0	(14.5)	(13.4)	(116.72)	N/A	N/A
2017e	0.0	(21.7)	(20.8)	(78.49)	N/A	N/A
2018e	0.0	(18.3)	(17.3)	(62.26)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$1.50
Market cap: US\$6m
Market: OTCQX

Share price graph (US\$)

Company description

International Stem Cell is an early-stage biotechnology company developing therapeutic, biomedical and cosmeceutical applications for its proprietary stem form of pluripotent stem cells – human parthenogenetic stem cells (hpSCs). Its lead candidate is a cell therapy treatment for Parkinson's disease.

Price performance

%	1m	3m	12m
Actual	(11.8)	(5.7)	(0.7)
Relative*	(13.7)	(12.4)	(15.8)

* % Relative to local index

Analyst

Maxim Jacobs

International Stem Cell (ISCO)

INVESTMENT SUMMARY

International Stem Cell (ISCO) is an early-stage cell therapy company currently in Phase I/IIa clinical trials to treat Parkinson's disease (PD), and is currently dosing the second cohort of patients (7 so far). The company recently reported positive interim clinical data from the first cohort of patients in the trial. The company is also preparing to initiate a Phase II trial in traumatic brain injury in the coming months. With its hpSC technology, ISCO has created 15 stem cell lines, each of which is a different HLA type. From this, it creates different cell types such as liver cells, neural cells and three-dimensional eye structures.

INDUSTRY OUTLOOK

ISCO's technology platform is based on human parthenogenetic stem cells (hpSCs). Parthenogenetic stem cells are created from unfertilized human eggs (oocytes) chemically activated to make the cells pluripotent. As hpSCs express fewer parental histocompatibility antigens, they reduce the risk of immune rejection.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2015	7.6	(5.0)	(4.6)	(129.29)	N/A	N/A
2016	7.2	(5.2)	(4.9)	(33.82)	N/A	N/A
2017e	7.6	(4.6)	(4.9)	(122.16)	N/A	N/A
2018e	8.3	(7.3)	(8.2)	(196.08)	N/A	N/A

Sector: Pharma & healthcare

Price: A\$0.36
Market cap: A\$17m
Market: ASX

Share price graph (A\$)

Company description

Kazia Therapeutics (formerly known as Novogen) has two clinical stage anti-cancer drugs GDC-0084 (targeting glioblastoma) and Cantrixil (targeting ovarian cancer) and a discovery-stage anti-tropomyosins program. GDC-0084 was inlicensed from Genentech, and Kazia is seeking other in-licence opportunities.

Price performance

%	1m	3m	12m
Actual	(12.8)	(15.0)	(63.4)
Relative*	(12.5)	(19.3)	(66.2)

* % Relative to local index

Analyst

Dr Dennis Hulme

Kazia Therapeutics (KZA)

INVESTMENT SUMMARY

Kazia Therapeutics (formerly Novogen) is developing two groups of anti-cancer compounds, including GDC-0084, a phase II-ready PI3K inhibitor licensed from Genentech that is intended for glioblastoma. The company has transferred the IND from Genentech and is undertaking final preparations for a Phase II study expected to start in Q417; an initial dose-optimisation study will precede a randomised trial in 228 first-line glioblastoma patients. It is undertaking a Phase I trial of its super-benzopyran drug Cantrixil, and has outlicensed its preclinical super-benzopyran program to Heaton-Brown Life Sciences. The 60-patient Phase I trial of Cantrixil in ovarian cancer which commenced in December 2016 is expected to report MTD in Q118; while the primary aim is to assess safety and tolerability, radiological responses and biomarkers will be assessed for indications of efficacy. Kazia has initiated a next-generation anti-tropomyosin drug discovery program supported by an A\$3m government grant. The company had A\$11.5m cash at June 2017.


INDUSTRY OUTLOOK

Kazia Therapeutics is a biotechnology company listed on the ASX and NASDAQ. Its two main drug technology platforms are super-benzopyrans (SBP) and a PI3K inhibitor. SBP compounds show potent activity against cancer stem cells.

Y/E Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	3.7	(10.6)	(11.6)	(2.8)	N/A	N/A
2017	8.6	(10.2)	(10.9)	(2.3)	N/A	N/A
2018e	7.5	(16.0)	(17.3)	(3.6)	N/A	N/A
2019e	17.6	(9.3)	(10.8)	(2.2)	N/A	N/A

Sector: Pharma & healthcare

Price: €7.78
Market cap: €134m
Market: Euronext Amsterdam

Share price graph (€)

Company description

Kiadis Pharma is a biotech company focused on cell-based immunotherapies to overcome complications associated with stem cell transplants in blood diseases. ATIR101 for leukaemia is in Phase II and will file for EU approval in Q117. ATIR201 (thalassemia) started a Phase I/II in December 2016.

Price performance

%	1m	3m	12m
Actual	(4.8)	50.3	(13.2)
Relative*	(3.4)	42.5	(26.0)

* % Relative to local index

Analyst

Juan Pedro Serrate

Kiadis Pharma (KDS)

INVESTMENT SUMMARY

Kiadis Pharma develops T cell-based therapies to address the issues associated with haematopoietic stem cell transplantation (HSCT). The company uses its Theralux technology to develop ATIR101 and ATIR201 as adjunct therapies to HSCT in leukaemia and thalassemia. Kiadis filed a Marketing Authorisation Application (MAA) of ATIR101 with the EMA in April 2017. A Phase III trial has been approved in several countries and has recently enrolled the first patient. ATIR101 has FDA Regenerative Medicine Advanced Therapy (RMAT) designation. ATIR201 is in a Phase I/II trial. Cash at 30 June 2017 was €10.7m. Kiadis raised €18m in Oct 2017 plus a debt facility of up to €15m.


INDUSTRY OUTLOOK

Kiadis's Theralux platform allows the infusion of lymphocytes from a partially matching (haploidentical) family member to the donor as it eliminates cells that could react against the host's immune cells and cause complications such as Graft vs Host Disease (GVHD). Positive one year data (Event-Free Survival and Overall Survival) from Phase II study with ATIR101 was presented at the ASH 58th Annual Meeting in San Diego, USA. OS was 61% for the ATIR101 arm vs 20% of a historic control group receiving HSCT only. GFRS was 57% for HSCT+ATIR101 vs 20% for the control group.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2014	0.0	(6.0)	(7.2)	(74.62)	N/A	N/A
2015	0.0	(15.9)	(17.4)	(136.50)	N/A	N/A
2016e	0.0	(8.6)	(10.0)	(71.58)	N/A	N/A
2017e	0.0	(11.9)	(13.5)	(96.42)	N/A	N/A

Sector: Pharma & healthcare

Price: €6.92
Market cap: €182m
Market Scale

Share price graph (€)

Company description

MagForce has a European approved nanotechnology-based therapy to treat brain cancer. Nanoparticles are injected into the tumour and activated by an external magnetic field, producing heat and thermally destroying or sensitising the tumour.

Price performance

%	1m	3m	12m
Actual	(8.8)	(11.2)	44.0
Relative*	(7.3)	(16.9)	22.4

* % Relative to local index

Analyst

Dr Daniel Wilkinson

MagForce (MF6)

INVESTMENT SUMMARY

MagForce is moving forward with its strategy to drive uptake and acceptance (in the US and Europe) of its NanoTherm nanoparticle-based therapy for cancer. In Germany, Magforce has six centres commercially capable (three utilised, c50 patients to date) of treating glioblastoma (GBM) patients. To accelerate uptake of NanoTherm treatment in Europe, we expect MagForce to look to expand from Germany into other countries (funded primarily by an up to €35m loan from the European Investment Bank). In the US, its subsidiary Magforce USA is in talks with the FDA to initiate a planned clinical trial in prostate cancer patients (potential launch in 2018). The company expects the trial to initiate in H217; data are expected 12 months later.

INDUSTRY OUTLOOK

MagForce's NanoTherm therapy has been designed to directly affect tumours from within, while sparing surrounding healthy tissue. Magnetic nanoparticles are directly injected into a tumour and are then heated in the presence of an external magnetic field generated by specialist equipment (NanoActivator). This can destroy or sensitise the tumour for additional treatment.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	2.6	(4.4)	(4.5)	(17.73)	N/A	N/A
2016	0.5	(6.6)	(7.2)	(27.81)	N/A	N/A
2017e	3.5	(3.8)	(4.6)	(17.41)	N/A	N/A
2018e	6.5	(4.3)	(5.6)	(21.13)	N/A	N/A

Sector: Pharma & healthcare

Price: €11.92
Market cap: €266m
Market FRA

Share price graph (€)

Company description

Medigene is a German biotech company with a core business in cancer immunotherapy. Dendritic cell (DC) vaccines are in Phase I/II clinical studies, while a T-cell receptor (TCR) candidate should enter the clinic in 2017.

Price performance

%	1m	3m	12m
Actual	(3.2)	(5.8)	27.1
Relative*	(1.6)	(11.9)	8.0

* % Relative to local index

Analyst

Dr Daniel Wilkinson

Medigene (MDG1)

INVESTMENT SUMMARY

Medigene is focused on the rapid development of its cancer immunotherapy technology platforms: dendritic cell (DC) cancer vaccines, adoptive T-cell therapy (TCR) and T-cell specific antibodies (TAB). Phase I/II studies are ongoing with DC vaccines for prostate cancer and acute myeloid leukaemia (investigator-sponsored) and acute myeloid leukaemia (Medigene). For TCRs, Medigene plans to receive approval for its first company led trial by year end. Important progress includes an alliance with bluebird bio, a prominent T-cell immunology company, to utilise its TCR technology platform to identify four therapeutic candidates against four targets. This is positive as it validates its TCR technology and offers potential upside from any development. Medigene is well-funded to execute its clinical programme, as of 30th September cash was €55.4m.


INDUSTRY OUTLOOK

Cancer immunotherapy is attracting huge biotech investor interest. Medigene's DC vaccine technology is a new generation, with multiple potential efficacy and manufacturing benefits over the forerunners, eg Provenge. The TCR programme has similarities to CAR-T products, but with potentially significant efficacy and safety advantages.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	6.8	(9.4)	(12.8)	(73.55)	N/A	N/A
2016	9.7	(10.2)	(11.3)	(55.51)	N/A	N/A
2017e	9.0	(17.6)	(18.6)	(88.63)	N/A	N/A
2018e	9.3	(19.5)	(20.2)	(91.11)	N/A	N/A

Sector: Pharma & healthcare

Price: A\$1.34
Market cap: A\$633m
Market: ASX

Share price graph (A\$)

Company description

Mesoblast is developing adult stem cell therapies based on its proprietary MPC and culture-expanded MSC platforms. It has six late-stage clinical trials across four areas.

Price performance

%	1m	3m	12m
Actual	5.5	(10.3)	10.5
Relative*	5.7	(15.3)	1.8

* % Relative to local index

Analyst

Dr Dennis Hulme

Mesoblast (MSB)

INVESTMENT SUMMARY

The potentially pivotal 60 pediatric patient acute graft vs host disease (GvHD) MSC-100-IV study may fully enroll in Q4 CY17 and report 28 day data in Q1 CY18 with 100 day data in Q2. A 360-patient Phase III of MPC-06-ID in chronic low back pain (CLBP) should enroll by Q1 CY18. The NIH funded Phase IIb (159 end-stage CHF patients with an LVAD) is fully enrolled with the 6-month LVAD weaning endpoint completing in Q1 CY18 and full data in Q3 CY18. The Phase III trial of MPC-150-IM in heart failure has enrolled over 400 of the 600 patient target. Cash on 30 Sept was US\$62.9m. The Q1 FY18 outflow was US\$20.3m. Mesoblast has a US\$90m equity finance facility.

INDUSTRY OUTLOOK

Mesoblast is the leading mesenchymal stem cell company, with nine clinical candidates in Phase II and III. It has a manufacturing alliance with Lonza. JCR Pharmaceuticals markets Mesoblast's GvHD therapy in Japan; Q1 FY18 royalties were US\$1.2m. Mallinckrodt did not exercise its exclusive option to license the CLBP or GvHD projects.

Y/E Jun	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2016	44.2	(86.3)	(87.4)	(0.20)	N/A	N/A
2017	3.4	(82.4)	(84.9)	(18.10)	N/A	N/A
2018e	6.7	(83.2)	(85.0)	(18.92)	N/A	N/A
2019e	9.0	(85.4)	(88.7)	(18.85)	N/A	N/A

Sector: Pharma & healthcare

Price: €2.31
Market cap: €79m
Market: FRA

Share price graph (€)

Company description

Mologen is a German biotech company developing cancer immunotherapies. The lead product is lefitolimod (MGN1703) for metastatic colorectal cancer maintenance, SCLC and HIV. Development of MGN1601, a therapeutic renal cell vaccine, would be reinitiated on successful out-licensing of lefitolimod.

Price performance

%	1m	3m	12m
Actual	(17.4)	(5.3)	42.9
Relative*	(15.9)	(11.4)	21.5

* % Relative to local index

Analyst

Dr Susie Jana

Mologen (MGN)

INVESTMENT SUMMARY

Mologen is developing novel immunotherapies for use in the post-chemo maintenance setting in cancer and for the treatment of infectious diseases. Mologen's efforts are focused on its lead product candidate lefitolimod. IMPALA a 540-pt pivotal study in metastatic colorectal cancer (mCRC) maintenance; recently completed full enrollment. Full data has been presented at ESMO 2017 for the 102-patient Phase II trial (IMPULSE) in small-cell lung cancer (SCLC). Topline results in the Phase I TEACH study to treat HIV (the first non-cancer study for MGN1703) have been announced. A 60-patient Phase I combination study of lefitolimod with Yervoy in solid tumours is now being conducted by MD Anderson, enrollment has started. Gross cash of €9.8m as of 30th September 2017. Mologen have signed a share subscription facility with GCF that will provide additional funding which should be sufficient to fund Mologen into mid 2018. Additionally, a licensing agreement soon to be signed with Chinese iPharma could provide up to €100m in revenue.

INDUSTRY OUTLOOK

Results for IMPALA are expected in 2018/19. Final overall survival (OS) data from IMPACT (Phase II in mCRC) and IMPULSE may offer fresh financing/partnering opportunities for lefitolimod before then.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	0.0	(20.4)	(20.5)	(0.99)	N/A	N/A
2016	0.0	(20.6)	(20.8)	(0.84)	N/A	N/A
2017e	3.0	(18.0)	(18.4)	(0.54)	N/A	N/A
2018e	0.0	(15.5)	(15.9)	(0.46)	N/A	N/A

Sector: Pcare & household prd

Price: 73.5p
Market cap: £51m
Market: AIM

Share price graph (p)

Company description

NetScientific is a transatlantic biomedical and healthcare technology group. Its portfolio of five core investments and one material investment is focused on three main sectors: digital health (Wanda), diagnostics (Vortex, ProAxis, Glycotest) and therapeutics (PDS Biotech).

Price performance

%	1m	3m	12m
Actual	8.1	80.4	13.1
Relative*	10.1	79.5	4.7

* % Relative to local index

Analyst

Maxim Jacobs

NetScientific (NSCI)

INVESTMENT SUMMARY

NetScientific has a focused portfolio of potentially disruptive biomedical and healthcare technology investments. Recent years saw significant strategic changes, including senior management restructuring, with a new highly experienced CEO on board, rationalisation of the portfolio and new funding. The current focus is on digital health, diagnostics and therapeutics with the portfolio consisting of four core investments in which it has controlling stakes (Vortex, Wanda, ProAxis and Glycotest) and one material investment (PDS). The aim is to bring these to commercialisation over the next two years, with the ultimate goal of an exit, realising value for investors. Vortex recently made its first commercial sale of the VTX-1 liquid biopsy system and ProAxis reported strong sales growth.


INDUSTRY OUTLOOK

NetScientific remains focused on sourcing, funding and building early- to mid-stage US and UK companies that are developing potentially breakthrough technologies in growing markets with unmet needs.

Y/E Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2015	0.1	(11.5)	(11.3)	(24.4)	N/A	N/A
2016	0.5	(12.6)	(12.3)	(20.6)	N/A	N/A
2017e	1.4	(10.1)	(7.8)	(9.8)	N/A	N/A
2018e	3.8	(10.4)	(11.8)	(14.1)	N/A	N/A

Sector: Pharma & healthcare

Price: SEK3.44
Market cap: SEK180m
Market: NASDAQ OTCQX

Share price graph (SEK)

Company description

NeuroVive Pharmaceutical is a Swedish biopharmaceutical company with deep expertise in mitochondrial medicine. It has a diversified portfolio in terms of indications and employs a dual strategy: it develops a core portfolio of assets for orphan diseases and seeks to out-license proprietary products for non-orphan indications.

Price performance

%	1m	3m	12m
Actual	(13.8)	(13.8)	0.0
Relative*	(11.4)	(16.6)	(8.0)

* % Relative to local index

Analyst

Dr Jonas Peciulis

NeuroVive Pharmaceutical (NVP)

INVESTMENT SUMMARY

NeuroVive Pharmaceutical is a mitochondrial medicine specialist with a diversified asset portfolio. NeuroVive's core portfolio, which the company aims to develop internally, targets orphan indications: traumatic brain injury (TBI) with NeuroSTAT, various genetic mitochondrial diseases with KL1333 and NVP015, and mitochondrial myopathy with NVP025. R&D news earlier this year regarding the positive outcome in a Phase IIa study with NeuroSTAT means that the drug candidate will proceed to a proof-of-concept study. The second most advanced product KL1333 was in-licensed from Yungjin Pharm in May 2017 and currently is in Phase I. Product portfolio for out-licensing includes NV556 and NVP022 for non-alcoholic steatohepatitis (NASH) and NVP024 for hepatocellular carcinoma (HCC).

INDUSTRY OUTLOOK

NeuroVive has a rather diversified portfolio in terms of indications; however, all the assets are based on improving mitochondrial metabolism and function. This puts NeuroVive among the very few experts in mitochondrial medicine in the industry, in our view. Central to NeuroVive's strategy is maintaining a network of KOLs, academic institutions and research organisations, which help to run innovative design and cost-effective studies.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2015	2.5	(89.1)	(89.6)	(300.43)	N/A	N/A
2016	0.0	(69.9)	(70.7)	(172.27)	N/A	N/A
2017e	0.6	(75.0)	(75.7)	(160.92)	N/A	N/A
2018e	0.6	(92.0)	(92.2)	(180.19)	N/A	N/A

Sector: Pharma & healthcare

Price: CHF10.85
Market cap: CHF194m
Market Swiss Stock Exchange

Share price graph (CHF)

Company description

Newron is a CNS-focused biotech. Xadago (partnered with Zambon, US WorldMeds, Meiji Seika, Sequirus) for PD has been launched in Europe and the US. Other pipeline assets include Sarizotan (Phase III for RS) and Evenamide (Phase II for schizophrenia).

Price performance

%	1m	3m	12m
Actual	(15.9)	(39.4)	(39.7)
Relative*	(16.4)	(42.0)	(48.6)

* % Relative to local index

Analyst

Dr Susie Jana

Newron Pharmaceuticals (NWRN)

INVESTMENT SUMMARY

Newron's lead product, Xadago (safinamide) for Parkinson's disease (PD) has been launched in 12 European countries and is generating sales through commercial partner Zambon (ex-Japan/Asia). Additionally, Xadago has been launched in the US by sublicensee US WorldMeds. Other pipeline assets include sarizotan for Rett syndrome, the pivotal trial STARS (placebo-controlled Phase II/III trial) to investigate breathing disorders associated with RS has initiated. Full data from the Phase II study of evenamide as an add-on to atypical antipsychotics, published in March 2017, demonstrated efficacy in terms of improvement on the symptoms of schizophrenia assessed by the Positive and Negative Syndrome Scale (PANSS). Newron raised CHF27m in 2017 in a private placement that it expects will help fund operations through 2019.

INDUSTRY OUTLOOK

Parkinson's disease is a growing market. Xadago could have a unique position, with once-a-day dosing and a clean safety profile.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	2.4	(17.6)	(18.3)	(117.21)	N/A	N/A
2016	6.7	(15.3)	(15.2)	(103.69)	N/A	N/A
2017e	15.1	(14.0)	(13.6)	(72.47)	N/A	N/A
2018e	17.9	(15.9)	(15.3)	(81.36)	N/A	N/A

Sector: Pharma & healthcare

Price: SEK17.50
Market cap: SEK750m
Market NASDAQ OMX First North

Share price graph (SEK)

Company description

Nuevolution is a Copenhagen-based biopharmaceutical company. Its patent protected Chemetics drug discovery platform enables the selection of drugs to an array of tough-to-drug disease targets. To date it has entered into 17 agreements with major pharmaceutical companies.

Price performance

%	1m	3m	12m
Actual	(11.6)	10.1	69.1
Relative*	(9.1)	6.5	55.5

* % Relative to local index

Analyst

Dr Susie Jana

Nuevolution (NUE)

INVESTMENT SUMMARY

Nuevolution's proprietary Chemetics DNA-encoded screening platform technology enables fast and accurate small molecule drug discovery. The technology has received powerful external validation, including three recent collaborations (Amgen, Almirall and Janssen) that could generate significant value in the coming years. In addition, we expect Nuevolution to progress at least one internally generated asset into clinical development in the near future. Net cash of SEK 142.3m (\$16.9m) (30th September 2017) suggests a cash runway into FY19.

INDUSTRY OUTLOOK

Significant promise is seen in DNA-encoded libraries due to the potential to rapidly develop small molecule drugs to 'tough-to-drug' targets. We continue to see major investment in the space from an array of companies, notably GSK, Roche and Novartis.

Y/E Jun	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	21.3	N/A	(151.9)	(397.0)	N/A	N/A
2017	120.3	N/A	(9.4)	(59.0)	N/A	N/A
2018e	182.8	N/A	45.9	70.0	25.0	17.9
2019e	133.9	N/A	(7.0)	(11.0)	N/A	N/A

Sector: Pharma & healthcare

Price: €0.99
Market cap: €50m
Market: Euronext Paris

Share price graph (€)

Company description

Onxeo is focused on orphan cancer and has three late-stage orphan oncology assets it could commercialise alone in Europe (Livatag, Beleodaq and Validive). Royalty-earning Beleodaq (belinostat) is launched in the US, along with two non-core, partnered, specialty products.

Price performance

%	1m	3m	12m
Actual	(26.1)	(75.9)	(59.6)
Relative*	(25.2)	(77.1)	(65.0)

* % Relative to local index

Analyst

Dr Jonas Pecilius

Onxeo (ONXEO)

INVESTMENT SUMMARY

Recently, Onxeo's AsiDNA demonstrated the first preclinical PoC data showing potential to be administrated intravenously. Another dataset showed that AsiDNA in combination with its Beleodaq (belinostat) had synergistic effect on suppressing malignant cell growth in various cancers, while having no effect on healthy cells. AsiDNA, a first-in-class DNA repair inhibitor, has already been tested in a Phase I trial in melanoma with promising safety and initial efficacy results. Onxeo aims to file the investigational new drug application by end-2017. Onxeo is analyzing the full data from its Phase III trial with Livatag, which did not meet primary endpoints, and will decide further steps. Recently, Onxeo out-licensed its Phase III ready orphan oncology asset Validive to Monopar Therapeutics for a total deal value of \$108m with up to double-digit royalties. Onxeo's Beleodaq is already launched in the US with partner Spectrum for r/r peripheral T-cell lymphoma (r/r PTCL), generating royalties for Onxeo.


INDUSTRY OUTLOOK

The patent expiry of blockbuster drugs and increased competition from generics has shifted the focus of the pharmaceutical industry to orphan drugs. Government support, as well as input from the regulatory bodies provide incentives for orphan drug developers.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	3.5	(20.4)	(20.0)	(43.53)	N/A	N/A
2016	4.4	(21.3)	(20.4)	(44.64)	N/A	N/A
2017e	10.2	(15.1)	(15.7)	(24.02)	N/A	N/A
2018e	2.6	(13.6)	(14.0)	(27.79)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$1.38
Market cap: US\$21m
Market: NASDAQ OTCQX

Share price graph (US\$)

Company description

Orexigen is a biopharmaceutical company focusing on obesity treatments. It will sell its sole product, Contrave, through its own salesforce in the US after taking back the rights from partner, Takeda. Contrave was launched in the US in Oct 2014 and approved in the EU in March 2015 under the trade name Mysimba.

Price performance

%	1m	3m	12m
Actual	(14.3)	(40.3)	(28.9)
Relative*	(16.1)	(44.5)	(39.7)

* % Relative to local index

Analyst

Maxim Jacobs

Orexigen Therapeutics (OREX)

INVESTMENT SUMMARY

Orexigen's obesity drug, Contrave, is an extended-release oral combination of long-marketed bupropion (Wellbutrin for depression) and Naltrexone (Revia for addiction). Now the leading branded obesity treatment in the US, Orexigen announced the acquisition of US rights to Contrave in the US from partner Takeda in mid-March 2016. The company is now marketing the drug with a new dedicated salesforce of 160 reps with a focus on the consumer. Contrave is approved under the brand Mysimba in most international markets. It has now launched in 17 countries, including South Korea, Spain, Poland, UK and Ireland. Launches in an additional 10-15 countries are expected by Q118. They also recently signed an agreement with Merck KGaA for Latin America including Mexico and Brazil.

INDUSTRY OUTLOOK

Orexigen is a biopharmaceutical company focusing on obesity treatments. Contrave was launched in the US in October 2014 and approved in the EU in March 2015, under the trade name Mysimba.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2015	24.5	(60.3)	(67.3)	(523.81)	N/A	N/A
2016	33.7	(134.6)	(138.1)	(972.82)	N/A	N/A
2017e	84.7	(134.9)	(137.7)	(713.33)	N/A	N/A
2018e	156.5	(64.4)	(68.9)	(353.59)	N/A	N/A

Sector: Pharma & healthcare

Price: SEK39.20
Market cap: SEK1354m
Market NASDAQ OMX Mid Cap

Share price graph (SEK)

Company description

Orexo is a Swedish speciality pharma company, with expertise in drug delivery/reformulation technologies (in particular sublingual formulations) and a US commercial infrastructure for opioid dependence therapy Zubsolv (also filed in Europe). Orexo also has two clinical assets and three preclinical programmes.

Price performance

%	1m	3m	12m
Actual	(8.2)	28.1	8.9
Relative*	(5.6)	23.9	0.1

* % Relative to local index

Analyst

Dr Susie Jana

Orexo (ORX)

INVESTMENT SUMMARY

Positive EBITDA and operating cash flow generation in an eighth consecutive quarter corner highlights a second profitable year. For 2018, US commercial and public formulary coverage has improved, which will have a positive impact on US Zubsolv sales from 1 January vs 2017 sales. IP infringement litigation remains an overhang. The court ruling on the '996 Zubsolv patent precludes Actavis generic launch before September 2019; Orexo has filed a separate '996 US IP infringement suit against Actavis for their Suboxone/Subutex generics. Zubsolv's IP portfolio includes patents extending to 2032 ('900 and '421) which with an appeal outcome on the invalidity of '330 expected around end-2017, represent significant hurdles ahead of generic launch. EMA has approved Zubsolv for Europe and partner Mundipharma should launch in H118.

INDUSTRY OUTLOOK

Opioid dependence diagnosis/treatment rates are low due to social stigma, limited access to therapy in parts of the US and affordability. Competition includes Suboxone film (Indivior), Bunavail (BDSI) and six generic bup/nal tablets.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2015	646.2	(99.9)	(203.6)	(607.3)	N/A	N/A
2016	705.9	74.4	35.6	84.4	46.4	7.3
2017e	614.2	70.1	21.1	30.6	128.1	6.6
2018e	714.1	129.1	111.2	257.5	15.2	8.4

Sector: Pharma & healthcare

Price: €3.02
Market cap: €103m
Market Madrid Stock Exchange

Share price graph (€)

Company description

Oryzon Genomics is a Spanish biotech focused on epigenetics. ORY-1001 (Phase I/IIa) is being explored for acute leukaemias and SCLC; ORY-2001, its CNS product, is due to enter Phase IIa trials in AD and MS, while newer asset ORY-3001 is being developed for certain orphan indications.

Price performance

%	1m	3m	12m
Actual	38.9	42.4	(33.1)
Relative*	37.6	39.7	(40.7)

* % Relative to local index

Analyst

Dr Jonas Peculis

Oryzon Genomics (ORY)

INVESTMENT SUMMARY

Oryzon's expertise lies in developing small molecule inhibitors for epigenetic targets. The lead oncology product ORY-1001 is a first-in-class inhibitor of lysine specific demethylase 1 (LSD1) with positive data from the Phase I/IIa in acute leukaemia announced in December 2016. Oryzon's former partner Roche will hand over the rights and the data from a Phase I trial with ORY-1001 in small cell lung cancer, expected early Q118. Oryzon will continue the development of ORY-1001 in both indications. Oryzon's lead CNS product, ORY-2001, targets Alzheimer's disease (Phase IIa planned), multiple sclerosis (Phase IIa initiated) and other neurodegenerative indications. ORY-3001 is a newer asset in preclinical development targeting certain orphan indications. The cash position was €33.9m at end Q317.


INDUSTRY OUTLOOK

Epigenetics is a relatively young field in terms of drug development. HDACs were among the first epigenetic therapeutics brought to market, and although effective, they have side effects. Oryzon is among the leading clinical stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and are expected to show a favourable safety/efficacy profile.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	7.2	0.7	(0.1)	(0.6)	N/A	69.3
2016	5.0	(3.7)	(4.7)	(17.0)	N/A	N/A
2017e	4.7	(4.0)	(5.4)	(17.3)	N/A	N/A
2018e	7.0	(4.7)	(5.6)	(16.3)	N/A	N/A

Sector: Pharma & healthcare

Price: 8.9p
Market cap: £277m
Market: LSE

Share price graph (p)

Company description

Oxford BioMedica is a leader in gene and cell therapy. The lentivector technology is wide ranging, covering in vivo and ex vivo vector products. The technology underpins the proprietary clinical development pipeline in addition to third party manufacturing contracts which add validation to the platform.

Price performance

%	1m	3m	12m
Actual	1.1	1.0	135.1
Relative*	3.0	0.5	117.7

* % Relative to local index

Analyst

Dr Susie Jana

Oxford BioMedica (OXB)

INVESTMENT SUMMARY

We expect OXB's strategic vision to come to further fruition through 2017/18. Novartis's CAR-T Kymriah (OXB provide the lentiviral vector) is now approved (in pediatric ALL) by the FDA with approvals in Europe and in DLBCL expected in the near future. OXB should now start earning royalties and substantial manufacturing fees from Kymriah. The possible spin-out/out-licensing of its priority development pipeline assets is ongoing (OXB-102, OXB-202, and OXB-302). As of 31st July, OXB have £22.1m in cash.

INDUSTRY OUTLOOK

Cell- and gene-therapy is the focus of much industry attention as it can dramatically alter the outcomes of many diseases. The proprietary lentivector platform is a flexible and efficient system that is promising in many indications.

Y/E Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2015	15.9	(12.5)	(16.6)	(0.49)	N/A	N/A
2016	27.8	(7.6)	(20.0)	(0.59)	N/A	N/A
2017e	40.4	2.4	(5.4)	(0.04)	N/A	24.9
2018e	47.2	10.5	2.9	0.22	40.5	43.6

Sector: Pharma & healthcare

Price: NZ\$0.37
Market cap: NZ\$173m
Market: NZSX

Share price graph (NZ\$)

Company description

Pacific Edge develops and sells a portfolio of molecular diagnostic tests based on biomarkers for the early detection and management of cancer. Tests utilising its Cxbladder technology for detecting and monitoring bladder cancer are sold in the US, New Zealand and Australia.

Price performance

%	1m	3m	12m
Actual	5.7	(24.9)	(31.2)
Relative*	3.7	(27.4)	(39.9)

* % Relative to local index

Analyst

Maxim Jacobs

Pacific Edge (PEB)

INVESTMENT SUMMARY

Pacific Edge develops and sells a portfolio of molecular diagnostic tests based on biomarkers for the early detection and management of cancer. Tests utilising its Cxbladder technology for detecting and monitoring bladder cancer are sold in the US, New Zealand and Australia. The company announced the signing of a Federal Supply Schedule to the Veterans Administration, allowing the marketing of Cxbladder tests within the organization - the largest integrated healthcare system in the US. The company has also signed an agreement recently with Tricare, which handles the healthcare for all uniformed service members and their families. The company also announced positive data from a user programme with Kaiser Permanente Southern California, which could lead to a commercial agreement with that group.

INDUSTRY OUTLOOK

Molecular diagnostics is a growing, but increasingly competitive field. Lead time from the initiation of user programmes to payment can be long.

Y/E Mar	Revenue (NZ\$m)	EBITDA (NZ\$m)	PBT (NZ\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	6.4	(14.9)	(15.5)	(4.1)	N/A	N/A
2017	9.3	(19.6)	(20.8)	(5.4)	N/A	N/A
2018e	18.5	(8.2)	(9.2)	(2.3)	N/A	N/A
2019e	41.8	12.3	11.2	1.9	19.5	10.4

Sector: Pharma & healthcare

Price: €2.45
Market cap: €150m
Market: FRA

Share price graph (€)

Company description

PAION is an emerging specialty pharma company developing anaesthesia products. Its lead product, remimazolam, is partnered with Yichang in China, Hana Pharma in S Korea, Cosmo in the US, Pendopharm in Canada and R-Pharm in CIS, Turkey and MENA.

Price performance

%	1m	3m	12m
Actual	(6.6)	(12.9)	2.8
Relative*	(4.9)	(18.5)	(12.6)

* % Relative to local index

Analyst

Dr Dennis Hulme

Paion (PA8)

INVESTMENT SUMMARY

Paion announced positive top-line results from a Phase III trial of remimazolam for procedural sedation in bronchoscopy in June, adding to the positive results of a Phase III colonoscopy trial. It has successfully completed Phase I studies to assess abuse potential, the final step of its US clinical development program. In the bronchoscopy trial 82.5% of patients on remimazolam achieved the primary outcome vs 3.4% on placebo and 34.8% on midazolam. While replacing midazolam as the primary target, planned changes in the US reimbursement of day procedures favouring less supervision by anaesthetists could further incentivise uptake of remimazolam. €29.6m cash at 30 September is sufficient to complete ongoing development and to file for procedural sedation in the US (filing by partner Cosmo expected H218), as well as a Japanese filing for remimazolam in general anaesthesia (GA, expected by mid-2018). Paion is seeking a partner in Japan. Paion has outlined a €20-25m programme that could see it restart Phase III studies in GA in Europe.

INDUSTRY OUTLOOK

Remimazolam has important advantages over competing products, including fast onset and offset of action with lower risk of cardiopulmonary events than the standard of care midazolam and propofol, and a reversal agent exists if there is over sedation.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	0.1	(34.1)	(34.0)	(55.7)	N/A	N/A
2016	4.3	(24.3)	(24.3)	(36.4)	N/A	N/A
2017e	5.9	(16.4)	(16.4)	(21.2)	N/A	N/A
2018e	3.5	(13.0)	(12.9)	(17.7)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$2.85
Market cap: US\$440m
Market: NASDAQ

Share price graph (US\$)

Company description

PDL has reinvented itself through a three-pronged strategy: investing in royalty streams of marketed and development-stage therapeutics and providing high-yield debt financing to device & diagnostic companies with near-term product launches.

Price performance

%	1m	3m	12m
Actual	(6.3)	(10.1)	29.5
Relative*	(8.3)	(16.5)	9.7

* % Relative to local index

Analyst

Maxim Jacobs

PDL BioPharma (PDLI)

INVESTMENT SUMMARY

PDL BioPharma is reinventing itself as a healthcare-focused finance company through a three-pronged strategy: investing in royalty streams, providing high-yield financing to life science companies with near-term product launches as well as through the purchase of approved drugs to be sold by Noden Pharma (which is currently a wholly owned subsidiary) on a high margin basis. This strategy allows investors to gain exposure in healthcare through a relatively low-risk, diversified vehicle.

INDUSTRY OUTLOOK

PDL BioPharma is one of the only companies that will give broad exposure to diverse royalty streams as well as corporate debt and high margin approved products.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2015	590.4	550.4	530.1	203.69	1.4	1.5
2016	244.3	193.1	175.5	77.72	3.7	4.6
2017e	295.2	208.8	189.5	76.75	3.7	8.1
2018e	104.2	23.8	6.4	8.75	32.6	N/A

Sector: Pharma & healthcare

Price: €2.30
Market cap: €511m
Market Madrid Stock Exchange

Share price graph (€)

Company description

PharmaMar is a Spanish biopharmaceutical group with a core focus on the development of marine-based drugs for cancer. Yondelis is approved in the EU and US, and partnered with Janssen (J&J) in the US and Taiho in Japan.

Price performance

%	1m	3m	12m
Actual	(29.1)	(38.0)	(7.8)
Relative*	(29.8)	(39.2)	(18.3)

* % Relative to local index

Analyst

Maxim Jacobs

PharmaMar (PHM)

INVESTMENT SUMMARY

PharmaMar has built a pipeline of first-in-class cancer drugs for development with strategic partners. Royalty income from Yondelis for soft tissue sarcoma in Japan and the US should drive strong profit growth from 2017. Top-line data from the Zepsyre (aka lurbinectedin and PM1183) Phase III in platinum-resistant ovarian cancer is due by early 2018. A second pivotal study is evaluating lurbinectedin in combination with doxorubicin in patients with small cell lung cancer. A Phase III in BRCA2-mutated breast cancer is planned, and pivotal studies in endometrial cancer have been flagged following a 44% response rate in Phase I.


INDUSTRY OUTLOOK

PharmaMar's oncology portfolio has been validated through multiple global partnerships, eg J&J in the US and Taiho in Japan (for Yondelis) and Chugai in certain EU countries (for Aplidin).

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	162.0	17.6	5.9	3.0	76.7	50.1
2016	164.0	(11.5)	(24.7)	(10.8)	N/A	N/A
2017e	171.2	0.9	(11.1)	(5.0)	N/A	44.2
2018e	191.6	39.6	27.2	12.2	18.9	25.6

Sector: Pharma & healthcare

Price: NOK24.60
Market cap: NOK530m
Market Oslo

Share price graph (NOK)

Company description

Photocure specialises in photodynamic therapy. Its bladder cancer imaging product is sold as Hexvix in Europe and Cysview in the US. Photocure handles the marketing in Nordic countries and the US, while Ipsen is its marketing partner in the EU.

Price performance

%	1m	3m	12m
Actual	(12.8)	8.4	(47.2)
Relative*	(8.7)	3.0	(53.0)

* % Relative to local index

Analyst

Maxim Jacobs

Photocure (PHO)

INVESTMENT SUMMARY

Photocure specialises in photodynamic therapy. Its bladder cancer imaging product (known as Hexvix in Europe and Cysview in the US) improves detection rates and helps prolong recurrence-free survival. The company recently announced positive Phase III data in the surveillance setting which may vastly increase their addressable market size as well as a new CMS rule which will increase reimbursement in the United States. Cevira is a Phase III-ready product for HPV-related diseases of the cervix and Visonac is a Phase III-ready product for acne. Photocure recently announced that the search for partners for Cevira and Visonac is expanded to include outright sale of those products, possible spinoffs or other strategic alternatives.

INDUSTRY OUTLOOK

Photocure is a photodynamic therapy company focused on bladder cancer imaging, HPV-related diseases and acne. As its products typically are a combination of a drug and a device, hurdles for generics are typically higher than with other therapeutics.

Y/E Dec	Revenue (NOKm)	EBITDA (NOKm)	PBT (NOKm)	EPS (öre)	P/E (x)	P/CF (x)
2015	134.7	(18.1)	(17.4)	(82.0)	N/A	N/A
2016	143.6	(8.0)	12.8	59.0	41.7	27.6
2017e	150.0	(33.1)	(43.9)	(204.0)	N/A	N/A
2018e	242.5	15.9	10.2	47.0	52.3	N/A

Sector: Pharma & healthcare

Price: €2.72
Market cap: €36m
Market Euronext Paris

Share price graph (€)

Company description

Pixium Vision develops retinal implants for patients with severe vision loss. Its lead product Iris is an epi-retinal implant, which received CE mark approval in 2016; a sub-retinal implant (Prima) is expected to start a human study in 2017.

Price performance

%	1m	3m	12m
Actual	(23.6)	(51.2)	(49.2)
Relative*	(22.7)	(53.5)	(55.9)

* % Relative to local index

Analyst

Pooya Hemami

Pixium Vision (PIX)

INVESTMENT SUMMARY

Pixium Vision is developing retinal bionic vision systems (BVS), or implants, that transform images into electrical signals to elicit visual perception in patients with severe retinal disease. It recently received clearance from the French regulatory agency to start a feasibility study of its next-generation Prima sub-retinal BVS on up to five patients with advanced Dry-ARMD. Pixium's Iris II was shown to improve visual performance in a 10-patient study, but it stopped operating as intended at approximately nine to 12 months post-implantation. Pixium has halted new Iris II implantations as it seeks to improve its longevity. Pixium held €13.4m in gross cash at 30 September 2017 and has up to c €6m available in an equity financing facility with Kepler Chevreux.


INDUSTRY OUTLOOK

Second Sight (EYES) is commercialising an epiretinal implant (Argus II) in the US and EU approved for Retinitis Pigmentosa. PRIMA has been designed and being evaluated in clinical studies as a potential treatment option initially for dry-AMD, a common disease in aging population and a significant unmet medical need.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	3.3	(14.6)	(15.6)	(122.88)	N/A	N/A
2016	2.5	(11.4)	(12.4)	(97.60)	N/A	N/A
2017e	2.8	(11.5)	(13.3)	(101.00)	N/A	N/A
2018e	3.0	(14.6)	(18.8)	(138.68)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$1.47
Market cap: US\$547m
Market NASDAQ, TASE

Share price graph (US\$)

Company description

Pluristem is a biotech company, headquartered in Israel, focused on the development of cell-based therapeutics derived from placenta. The company is advancing PLX-PAD for critical limb ischemia (CLI) with a Phase III study on hip fracture. PLX-R18 is being advanced for acute radiation syndrome and hematopoietic cell transplant.

Price performance

%	1m	3m	12m
Actual	(1.2)	25.4	(13.2)
Relative*	(2.8)	19.6	(16.8)

* % Relative to local index

Analyst

Maxim Jacobs

Pluristem Therapeutics (PSTI)

INVESTMENT SUMMARY

Pluristem Therapeutics is developing allogenic cell therapies derived from donated placental tissue. The company is advancing PLX-PAD in its Phase III study of critical limb ischemia (CLI) and Phase II study of intermittent claudication (IC), with the latter expecting results in early 2018. Additionally the company received an orphan designation for PLX-R18 for acute radiation syndrome (ARS) currently in non-human primate studies and expanded its Phase I study for support of stem cell transplant to additional sites.


INDUSTRY OUTLOOK

Pluristem has been investigating the potential therapeutic benefit of cells derived from the placenta which offers a rich supply of cells of multiple lineages from tissue that would otherwise be medical waste. Although these cells are not stem cells and lack the immortality and pluripotency to meet that definition, they secrete a wide array of cytokines and growth factors and can exert a potent influence on the function of other cells in the body.

Y/E Jun	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	2.8	(25.5)	(23.2)	(29.22)	N/A	N/A
2017	0.0	(30.2)	(27.8)	(31.81)	N/A	N/A
2018e	0.0	(42.4)	(43.3)	(43.68)	N/A	N/A
2019e	N/A	N/A	N/A	N/A	N/A	N/A

Sector: Pharma & healthcare

Price: €11.39
Market cap: €93m
Market Euronext Amsterdam

Share price graph (€)

Company description

Probiodrug is a biopharma company developing its clinical pipeline for the treatment of Alzheimer's. Lead product candidate, PQ912, has entered Ph IIa. PQ912 is a small molecule inhibitor of QC, which is essential for the formation of pGlu-Abeta. Two further products are in preclinical stages.

Price performance

%	1m	3m	12m
Actual	(15.0)	(20.1)	(36.7)
Relative*	(13.8)	(24.2)	(46.0)

* % Relative to local index

Analyst

Dr Jonas Pecilius

Probiodrug (PBD)

INVESTMENT SUMMARY

Probiodrug is developing a clinical pipeline focusing on the novel target of pGlu-Abeta, a toxic variant of amyloid-beta (Abeta) that has been implicated in the initiation and sustainment of the pathological cascade that leads to Alzheimer's disease (AD). Lead candidate PQ912 is an inhibitor of the enzyme glutaminyl cyclase, which is essential for the formation of pGlu-Abeta. Initial results from the Phase IIa study, SAPHIR, study were reported on 12 June. While primarily safety/tolerability study, several secondary endpoints especially piqued our interest, with CSF biomarker, EEG and a couple of cognitive tests pointing to a positive overall picture of the dataset. Probiodrug has started preparations for the Phase IIb development. Recently new preclinical data also showed that PQ912 demonstrated efficacy in Huntington's disease in an animal model. Subject to further preclinical work, PQ912 could be fast-tracked to the clinic.


INDUSTRY OUTLOOK

There are 44m dementia sufferers worldwide, 60% of whom have AD. The lack of disease-modifying therapies leaves a vast unmet clinical need. This, combined with increasing understanding of the disease process and the development of biomarkers, has led to increased optimism that a disease-modifying therapy may be found.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	0.0	(13.3)	(13.5)	(196.10)	N/A	N/A
2016	0.0	(13.7)	(13.8)	(181.30)	N/A	N/A
2017e	0.0	(10.5)	(9.6)	(104.25)	N/A	N/A
2018e	0.0	(8.6)	(8.7)	(105.76)	N/A	N/A

Sector: Pharma & healthcare

Price: €2.96
Market cap: €33m
Market Euronext Paris

Share price graph (€)

Company description

Quantum Genomics is a biopharmaceutical company developing QGC001, a brain aminopeptidase A inhibitor for the treatment of hypertension and heart failure. Its mechanism is implicated in the 25% of patients resistant to treatment.

Price performance

%	1m	3m	12m
Actual	(6.9)	(4.5)	(57.0)
Relative*	(5.8)	(9.1)	(62.7)

* % Relative to local index

Analyst

Maxim Jacobs

Quantum Genomics (ALQGC)

INVESTMENT SUMMARY

Quantum Genomics is investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and heart failure. In June, they announced the results from their 34-patient Phase IIa study of QGC001 for the treatment of mild to moderate arterial hypertension. It showed a 2.7 mmHg placebo-adjusted reduction in ambulatory systolic blood pressure (SBP) and a 4.7 mmHg reduction in in-office SBP. The follow-up 250 patient NEW-HOPE study was recently launched. Data in heart failure is expected in H118.

INDUSTRY OUTLOOK

The angiotensin pathway is one of the primary methods of modulating blood pressure and it is the target of some of the most successful anti-hypertensive drugs: angiotensin converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs). However, there is a parallel pathway in the brain responsible for the secretion of vasopressin and heart rate that is unaddressed by these classes of drug and that is being targeted by Quantum Genomics.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	0.1	(4.3)	(4.5)	(54.70)	N/A	N/A
2016	0.0	(6.2)	(6.2)	(59.79)	N/A	N/A
2017e	0.0	(8.6)	(8.6)	(75.96)	N/A	N/A
2018e	0.0	(10.9)	(11.9)	(91.00)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$4.63
Market cap: US\$99m
Market: NASDAQ, TASE

Share price graph (US\$)

Company description

RedHill Biopharma is a specialty pharma company with a broad R&D pipeline focusing on gastrointestinal and inflammatory diseases and also promotes three GI products in the US. The most advanced programs are TALICIA (RHB-105) for H. pylori infection, RHB-104 for Crohn's disease and NTM infections and Bekinda for gastroenteritis and IBS-D.

Price performance

%	1m	3m	12m
Actual	(12.3)	(43.9)	(59.0)
Relative*	(14.2)	(47.9)	(65.3)

* % Relative to local index

Analyst

Dr Jonas Peciulis

RedHill Biopharma (RDHL)

INVESTMENT SUMMARY

RedHill has a broad R&D pipeline, but is focusing on GI and inflammatory diseases. The most advanced assets are TALICIA (RHB-105) for H. pylori infection (top-line results from confirmatory Phase III expected in H218); RHB-104 for Crohn's disease (top-line results from first Phase III expected in mid-2018) and non-tuberculous mycobacteria infections (pivotal Phase III trial to start in H118); and BEKINDA for both gastroenteritis (successful top-line results from first Phase III announced in June) and diarrhoea-predominant IBS (positive top-line Phase II results announced in October). RedHill is building a commercial business in the US and has initiated promotion of three GI products (Donnatal, EnteraGam and Esomeprazole Strontium DR Capsules 49.3mg) with sales of \$1.5m booked in Q317.

INDUSTRY OUTLOOK

RedHill's main focus on GI and inflammation include a range of conditions, which although can be treated with a variety of innovative and established products, there is still an unmet need in each of the diseases. In our view, carefully positioned, innovative solutions for the patients will attract attention.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2015	0.0	(21.9)	(21.1)	(19.03)	N/A	N/A
2016	0.1	(30.5)	(29.4)	(22.85)	N/A	N/A
2017e	7.5	(49.7)	(47.4)	(24.88)	N/A	N/A
2018e	30.0	(34.2)	(34.4)	(13.56)	N/A	N/A

Sector: Pharma & healthcare

Price: A\$0.12
Market cap: A\$26m
Market: ASX

Share price graph (A\$)

Company description

Regeneus is a clinical-stage regenerative medicine company developing innovative cell-based therapies for the human & animal health markets.

Price performance

%	1m	3m	12m
Actual	4.2	0.0	(34.2)
Relative*	4.4	(5.6)	(39.4)

* % Relative to local index

Analyst

Dr Dennis Hulme

Regeneus (RGS)

INVESTMENT SUMMARY

Regeneus is developing its mesenchymal stem cell technology for musculoskeletal conditions in humans (Progenza) and animals (CryoShot). In December 2016 Regeneus entered a US\$16.5m collaboration with AGC Asahi Glass (AGC) for manufacture of Progenza cells for the Japanese market. Regeneus and AGC have formed a 50:50 JV for clinical development and commercialisation of Progenza in Japan – we expect the JV to sub-license one or more partners to undertake clinical trials in a number of indications. Japanese legislation offers an accelerated path to market for regenerative medicines. Progenza therapy led to meaningful reductions in osteoarthritis knee pain in Phase I. Regeneus holds global rights to autologous cancer vaccine technologies for human (RGS4K, in Phase I) and veterinary (Kvax) applications. Its Sygenus topical secretions technology produced better pain relief than morphine in recent preclinical studies.


INDUSTRY OUTLOOK

Regeneus' strategy is to focus on early-stage product development, then partner. In addition to the AGC deal for Progenza in Japan, it has partnered with a global animal health company for CryoShot Canine. It will seek to identify wider applications of Progenza, beyond osteoarthritis.

Y/E Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	1.7	(3.4)	(3.6)	(1.70)	N/A	N/A
2017	10.0	4.9	3.3	1.57	7.6	7.0
2018e	7.8	2.1	1.9	0.89	13.5	7.7
2019e	1.2	(4.2)	(4.4)	(2.08)	N/A	N/A

Sector: Pharma & healthcare

Price: 1.8p
Market cap: £57m
Market: LSE

Share price graph (p)

Company description

ReNeuron is a UK biotech company developing allogeneic cell therapies: CTX neural stem cell products for stroke disability (Phase IIa) and critical limb ischaemia (Phase I); and human retinal progenitor cells for retinitis pigmentosa (Phase I/II).

Price performance

%	1m	3m	12m
Actual	(14.3)	4.4	(40.0)
Relative*	(12.7)	3.8	(44.4)

* % Relative to local index

Analyst

Maxim Jacobs

ReNeuron Group (RENE)

INVESTMENT SUMMARY

ReNeuron is focused on two cell therapy-based programmes. This includes the CTX neural stem cell programme which recently announced that positive response rates in key measures were sustained after 12 months of treatment. They also recently announced they will be moving forward with a Phase IIb in the US with data expected around H219. It also includes the hRPC (human retinal progenitor cells) programme for retinitis pigmentosa (currently in Phase II). It will also be commencing a Phase II trial in cone-rod dystrophy. ReNeuron has promising early data for its exosome nanomedicine platform in oncology.

INDUSTRY OUTLOOK

Limited drug development has targeted chronic stroke to date, which is the area in which ReNeuron is attempting to demonstrate a meaningful reduction in disability. If shown, it would offer a compelling case for further development and/or partnering.

Y/E Mar	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2016	0.0	(13.6)	(12.8)	(0.44)	N/A	N/A
2017	0.0	(19.7)	(18.2)	(0.49)	N/A	N/A
2018e	0.0	(32.6)	(32.3)	(0.96)	N/A	N/A
2019e	0.0	(34.0)	(34.5)	(1.03)	N/A	N/A

Sector: Pharma & healthcare

Price: €16.60
Market cap: €830m
Market: Madrid Stock Exchange

Share price graph (€)

Company description

Laboratorios Farmacéuticos ROVI is a fully integrated Spanish speciality pharmaceutical company involved in the development, in-licensing, manufacture and marketing of small molecule and speciality biologic drugs with a particular expertise in low molecular weight heparin (LMWH).

Price performance

%	1m	3m	12m
Actual	0.0	3.6	41.6
Relative*	(0.9)	1.7	25.5

* % Relative to local index

Analyst

Dr Susie Jana

ROVI Laboratorios Farmaceuticos (ROVI)

INVESTMENT SUMMARY

ROVI, a profitable, speciality healthcare company, markets ~30 proprietary and in-licensed products across nine core franchises mainly in its domestic Spanish market. ROVI is at a major inflection point; it has launched its internally developed biosimilar enoxaparin into the first European market (Germany) ahead of any competition; this is a key driver of sales and operating growth in the medium term. R&D progress continues with the long-acting DORIA (schizophrenia) and letrozole (breast cancer) having entered Phase III and Phase I of clinical-stage development respectively.

INDUSTRY OUTLOOK

ROVI has a strong presence in the Spanish heparin market (and select international markets through partners), where it has been manufacturing and marketing its flagship product Hibor (second-generation LMWH) since 1998.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	246.0	31.8	22.9	43.99	37.7	35.7
2016	265.2	39.3	30.3	58.11	28.6	28.0
2017e	277.3	28.7	19.6	36.88	45.0	18.0
2018e	294.7	39.3	29.7	55.63	29.8	36.1

Sector: Pharma & healthcare

Price: 54.89PLN
Market cap: PLN756m
Market: Warsaw Stock Exchange

Share price graph (PLN)

Company description

Selvita is an R&D and drug discovery services company. It operates two main business units: Innovations Platform (internal R&D pipeline) and Research Services (medicinal chemistry/biology, biochemistry).

Price performance

%	1m	3m	12m
Actual	27.7	9.9	115.5
Relative*	33.2	13.3	71.9

* % Relative to local index

Analyst

Dr Jonas Peciusis

Selvita (SLV)

INVESTMENT SUMMARY

Selvita is an R&D and drug discovery services company. In 9M17 sales jumped by 65% y-o-y reflecting strong organic growth and an upfront payment from Berlin Chemie/Menarini. Selvita out-licensed its lead drug SEL24's to Menarini in March 2017 with a total potential value of the deal of €89.1m. SEL24 is dual PIM/FLT3 inhibitor in Phase I/II for AML and the first such compound to progress to Phase I/II, to our knowledge. In October, the FDA has placed a full clinical hold on the trial due to an adverse event classified as possibly related to the treatment. Selvita will respond to the FDA with all required data and study modification requested by the agency. Second lead product is SEL120, a CDK8 inhibitor, partnered with the Leukemia & Lymphoma Society for AML and is undergoing IND-enabling studies. Multiple collaborations signed with partners such as Merck KGaA, H3 Biomedicine (Eisai) and JV (Nodthera) with Epidarex Capital validate Selvita's research capabilities.


INDUSTRY OUTLOOK

The profiles of SEL24 and SEL120 are potentially unique when compared to existing clinical-stage competitors and both candidates may offer efficacy advantages. Contract research is a fiercely competitive, but still rapidly growing market and we believe Selvita's geographical location and lower cost benefits make it well placed to compete.

Y/E Dec	Revenue (PLNm)	EBITDA (PLNm)	PBT (PLNm)	EPS (gr)	P/E (x)	P/CF (x)
2015	56.1	10.2	7.5	83.58	65.7	N/A
2016	66.7	8.3	4.6	64.22	85.5	N/A
2017e	106.0	17.9	11.4	81.31	67.5	61.3
2018e	99.2	5.8	0.3	1.96	2800.5	N/A

Sector: Pharma & healthcare

Price: US\$2.93
Market cap: US\$153m
Market: NASDAQ

Share price graph (US\$)

Company description

Sierra Oncology is developing new therapies targeting the DNA damage response to treat cancer. It is in Phase I clinical trials of SRA737, an inhibitor of Chk1, both as a monotherapy and in combination with chemotherapy. It is also in IND enabling studies of SRA141, a Cdc7 inhibitor with an IND expected in late 2017.

Price performance

%	1m	3m	12m
Actual	51.8	91.5	92.8
Relative*	48.5	77.8	63.3

* % Relative to local index

Analyst

Maxim Jacobs

Sierra Oncology (SRRA)

INVESTMENT SUMMARY

Sierra Oncology is a drug developer targeting the DNA damage response (DDR) network to treat cancer. The company has two Phase I trials with SRA737 targeting checkpoint kinase 1 (Chk1) in patients with genetic tumor types expected to respond to the drug. Inhibition of Chk1 is lethal in cells with defective p53 (among others), one of the most common cancer mutations, and may also be potentiated by low-dose chemotherapy. Interim results are expected in early 2018. Sierra also has the cell division cycle 7 (Cdc7) inhibitor SRA141 in preclinical testing.

INDUSTRY OUTLOOK

Chk1 inhibition, the mode of action for Sierra's lead compound, has an exceptionally high potential to address multiple cancers of different lineages due to the ubiquity of the mutations it has demonstrated synthetic lethality with.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2015	0.0	(32.5)	(32.6)	(226.2)	N/A	N/A
2016	0.0	(41.6)	(41.4)	(136.9)	N/A	N/A
2017e	0.0	(38.2)	(38.1)	(76.0)	N/A	N/A
2018e	0.0	(43.1)	(42.8)	(76.6)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$2.48
Market cap: US\$85m
Market: NASDAQ

Share price graph (US\$)

Company description

Sunesis Pharmaceuticals is a pharmaceutical company focused on oncology. The company has developed SNS-062, a BTK inhibitor for CLL for Imbruvica refractory patients currently in Phase I/II.

Price performance

%	1m	3m	12m
Actual	(7.5)	13.2	(35.8)
Relative*	(9.5)	5.1	(45.6)

* % Relative to local index

Analyst

Maxim Jacobs

Sunesis Pharmaceuticals (SNSS)

INVESTMENT SUMMARY

Sunesis is a pharmaceutical company developing small molecule oncology drugs. Its lead program is SNS-062, a novel non-covalent, oral BTK inhibitor that may work in Imbruvica relapsed and refractory patients. Data from a Phase Ia study in healthy volunteers was recently presented and indicated an attractive PK/PD profile with twice a day dosing. The drug is in a Phase Ib/II dose escalation/expansion trial targeting completion by September 2018. The trial will enroll up to seven dose cohorts and up to 124 patients with confirmed Imbruvica resistance mutations.


INDUSTRY OUTLOOK

Sunesis is an oncology company with an early stage asset with a validated target targeting patients that are in B-cell malignancies.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2015	3.1	(35.8)	(36.7)	(301.72)	N/A	N/A
2016	2.5	(36.3)	(38.0)	(242.37)	N/A	N/A
2017e	0.7	(34.9)	(35.9)	(148.01)	N/A	N/A
2018e	0.0	(33.1)	(34.6)	(96.34)	N/A	N/A

Sector: Pharma & healthcare

Price: ¥217.00
Market cap: ¥11400m
Market: Tokyo

Share price graph (¥)

Company description

SymBio is a Japanese specialty pharma company with a focus on oncology and haematology. Treakisym is SymBio's branded formulation of bendamustine HCl. Rigoserib is in-licensed from Onconova.

Price performance

%	1m	3m	12m
Actual	(6.1)	(4.0)	(14.9)
Relative*	(5.3)	(15.2)	(28.6)

* % Relative to local index

Analyst

Dr Dennis Hulme

SymBio Pharmaceuticals (4582)

INVESTMENT SUMMARY

SymBio is well on the way to becoming a key speciality pharma partner for Asia-Pacific markets. The company has in-licensing deals for two orphan blood cancer products. Treakisym is approved for r/r low grade NHL/MCL and during 2016 received approvals in CLL and first-line low grade NHL/MCL; these recent approvals could more than double sales (JPY4.7bn in 2016). In August SymBio initiated a Phase III trial in Japan of Treakisym in r/r diffuse large B-cell lymphoma, while in September it in-licensed liquid formulations that will provide Treakisym with patent protection that extends to 2031. Intravenous Rigoserib is in development for myelodysplastic syndromes (MDS) and has started a pivotal Phase III global study; SymBio is enrolling patients in Japan and an interim analysis is expected during Q417 or early 2018, with topline data due in H218. SymBio intends to participate in a planned global trial of high-dose oral rigoserib in untreated higher-risk MDS patients.


INDUSTRY OUTLOOK

SymBio is focused on in-licensing niche opportunities in hard-to-treat indications often overlooked by big pharma. An in-house screening process to select additional pipeline candidates for development and commercialisation will be key to driving operating leverage.

Y/E Dec	Revenue (¥m)	EBITDA (¥m)	PBT (¥m)	EPS (fd) (¥)	P/E (x)	P/CF (x)
2015	1933.0	(2527.0)	(2630.0)	(81.3)	N/A	N/A
2016	2368.0	(2101.0)	(2317.0)	(59.0)	N/A	N/A
2017e	3599.0	(3903.0)	(4000.0)	(82.4)	N/A	N/A
2018e	4248.0	(1987.0)	(1999.0)	(39.5)	N/A	N/A

Sector: Pharma & healthcare

Price: NOK16.90
Market cap: NOK889m
Market: Oslo

Share price graph (NOK)

Company description

Targovax is an immuno-oncology company headquartered in Oslo, Norway, with two technology platforms that are being developed in a number of oncological indications. ONCOS-102 is an oncolytic virus technology. TG is a therapeutic cancer vaccine platform comprising of peptides mimicking the most common RAS oncogenic mutations.

Price performance

%	1m	3m	12m
Actual	21.6	(12.9)	47.9
Relative*	27.2	(17.2)	31.8

* % Relative to local index

Analyst

Dr Jonas Paciulis

Targovax (TRVX)

INVESTMENT SUMMARY

Targovax is an immuno-oncology (IO) company specialising in two distinct, but complementary approaches. ONCOS-102 is a genetically engineered adenovirus being tested in advanced melanoma, mesothelioma and three other indications run by partners. From the TG platform, two mutant RAS-specific, neo-antigen cancer vaccines are in development for colorectal and pancreatic cancers, for which interim Phase I/II results with positive survival data were presented at ASCO in June 2017. Targovax's core proposition is to use its products as immune response primers and combine with other anticancer therapies, such as checkpoint inhibitors, for increased efficacy.


INDUSTRY OUTLOOK

Checkpoint inhibitors (CPIs) gained popularity over the past several years, however, a large proportion of patients do not respond to CPIs. Both Targovax's platform technologies are designed to prime immune response to cancers, which offers synergies for use in combination with other immuno-oncology therapies.

Y/E Dec	Revenue (NOKm)	EBITDA (NOKm)	PBT (NOKm)	EPS (fd) (öre)	P/E (x)	P/CF (x)
2015	0.1	(89.5)	(89.9)	(505.87)	N/A	N/A
2016	0.0	(119.2)	(122.7)	(354.65)	N/A	N/A
2017e	0.0	(123.5)	(122.7)	(258.36)	N/A	N/A
2018e	0.0	(125.8)	(124.2)	(235.30)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$5.35
Market cap: US\$5m
Market: NASDAQ, TASE

Share price graph (US\$)

Company description

Therapix Biosciences is an Israeli pharmaceutical company developing two cannabinoids to treat Tourette syndrome and mild cognitive impairment. It is currently in Phase IIa and soon to begin Phase I, respectively, and owns or licenses several IPs for cannabinoid nasal and sublingual administration.

Price performance

%	1m	3m	12m
Actual	7.0	(6.1)	(33.3)
Relative*	4.7	(12.9)	(43.5)

* % Relative to local index

Analyst

Maxim Jacobs

Therapix Biosciences (TRPX)

INVESTMENT SUMMARY

Therapix is investigating the potential of new formulations of cannabinoids to address underserved diseases of the brain. The lead clinical program, THX-TS01, is currently in Phase II trials testing its potential for treating Tourette's in adults (readout H118). THX-ULD01, for the treatment of traumatic brain injury (TBI) is scheduled to begin Phase I trials in Q118. Therapix recently announced it is expanding its cannabinoid-based clinical pipeline to potentially treat obstructive sleep apnea (OSA) with THX-OSA01, an oral THC/PEA formulation, in a thirty-patient Phase IIa trial. In addition, Therapix is exploring the potential of a cannabinoid composition containing an antibacterial agent for the treatment of infectious diseases in preclinical trials.

INDUSTRY OUTLOOK

Diseases of the brain are a major unmet medical need with few effective or approved therapies for a host of diseases. Cannabinoids have had promising data in many indications in the area and is a class that has received a lot of interest.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2015	N/A	N/A	N/A	N/A	N/A	N/A
2016	0.0	(1.7)	(1.7)	(179.9)	N/A	N/A
2017e	0.0	(4.0)	(4.3)	(118.4)	N/A	N/A
2018e	0.0	(7.7)	(7.7)	(200.1)	N/A	N/A

Sector: Pharma & healthcare

Price: €2.60
Market cap: €161m
Market: Euronext Paris

Share price graph (€)

Company description

Transgene is a French company developing immunotherapy agents for cancer and infectious diseases. Oncolytic virus Pexa-Vec (Phase III for HCC) and cancer vaccine TG4010 (Phase II for NSCLC) are the lead clinical candidates.

Price performance

%	1m	3m	12m
Actual	(18.0)	(23.8)	(4.1)
Relative*	(17.0)	(27.5)	(16.9)

* % Relative to local index

Analyst

Dr Daniel Wilkinson

Transgene (TNG)

INVESTMENT SUMMARY

Transgene is focused on the development of its cancer immunotherapy products (oncolytic virus Pexa-Vec, MUC1 cancer vaccine TG4010 and TG4001 for HPV) in combination with immune checkpoint inhibitors (ICIs) and infectious disease programmes (TG1050 for HBV). The company is running 10 clinical trials, including a Phase 2 trial testing TG4010+Opdivo in 2L NSCLC, a Phase 2 with Pexa-Vec+Opdivo in 1L advanced liver cancer, a Phase 1b/2 trial of TG4001 in HPV positive cancers in combination with avelumab, a Phase 1 trial with Pexa-Vec+Yervoy in solid tumours, a Phase 1/2 of Pexa-Vec+metronomic cyclophosphamide in HER2 negative breast cancer. Transgene and partner Sillajen are running a global 600-patient Phase 3 study in liver cancer. Transgene has a collaboration with BMS to test TG4010 in combination with Opdivo and chemotherapy in 1L and 2L NSCLC. Gross cash at 30 September 2017 was €40m. Transgene recently raised gross €14.4m by the way of a capital increase, extending financial visibility until mid-2019.

INDUSTRY OUTLOOK

Immunotherapies are among the most promising class of products for cancer. Increased attention is now being paid to the use of combination therapy approaches to improve cancer response rates further.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	9.9	(25.7)	(28.9)	(78.08)	N/A	N/A
2016	10.3	(20.4)	(23.1)	(42.90)	N/A	N/A
2017e	8.3	(32.0)	(35.0)	(62.11)	N/A	N/A
2018e	8.6	(33.6)	(36.8)	(65.19)	N/A	N/A

Sector: Pharma & healthcare

Price: €1.42
Market cap: €30m
Market: Euronext Paris

Share price graph (€)

Company description

TxCell is developing regulatory T-cell therapies against autoimmune and inflammatory disorders. It is now focused on a novel CAR Treg technology platform. A clinical trial in transplantation may start in 2018. Ovasave for Crohn's disease is at clinical stage but is on hold.

Price performance

%	1m	3m	12m
Actual	(6.0)	(15.0)	(43.1)
Relative*	(4.8)	(19.1)	(50.7)

* % Relative to local index

Analyst

Dr John Savin

TxCell (TXCL)

INVESTMENT SUMMARY

TxCell has a promising humanised CAR-Treg product that can be developed to control graft rejection in solid organ transplant. A lung transplant trial is planned to start in late 2018. CAR Tregs offer a powerful and versatile new approach to immune system disorders like multiple sclerosis. A revised €15m financing package will probably be used in 2018 as warrants look unlikely to be exercised unless a deal or significant news is announced before late February. Cash on 30 Sept was €7m. Shares in issue are now 21.4m after further warrant conversions.

INDUSTRY OUTLOOK

TxCell is focused on CAR Treg development using chimeric antigen receptor (CAR) technology similar to that in CAR T-cell cancer therapy. Developing a humanised CAR Treg is an important step. Progress has been made in CAR Treg manufacturing. A granted European patent offers broad protection. Novartis now has a small Treg study showing big pharma interest. OvaSave is not now in active development.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2015	0.9	(10.8)	(10.8)	(88.4)	N/A	N/A
2016	0.2	(11.9)	(12.7)	(97.5)	N/A	N/A
2017e	0.3	(8.9)	(9.1)	(42.8)	N/A	N/A
2018e	0.3	(11.1)	(11.4)	(44.3)	N/A	N/A

Sector: Pharma & healthcare

Price: 12.2p
Market cap: £64m
Market: AIM

Share price graph (p)

Company description

Vernalis is a UK speciality pharma company with an FDA-approved, prescription-only cough cold treatment, Tuzistra XR; an FDA approved amoxicillin, Moxatag; and a late-stage US cough cold pipeline of four products.

Price performance

%	1m	3m	12m
Actual	(1.0)	(26.9)	(63.8)
Relative*	0.8	(27.2)	(66.5)

* % Relative to local index

Analyst

Dr Susie Jana

Vernalis (VER)

INVESTMENT SUMMARY

Tuzistra XR prescriptions (Rx) grew threefold to ~35k in FY16/17 (2nd year on the market) vs ~12k in FY15/16. Investment into addressing the barriers to higher Tuzistra XR prescribing is translating into higher Rx rates, although this has not been matched by revenue growth due to higher inventory stocking in the same period last year. In H217 FDA issued partner Tris with two complete response letters to Vernalis's CCP-07 and CCP-08 NDAs and we now assume a one-year delay to approval and launch for both. Near term, execution is critical; successful operational execution in FY18 will lay important foundations for subsequent launches from its extended release (ER) prescription only (Rx) cough cold pipeline.

INDUSTRY OUTLOOK

Generic IR liquid products dominate the US Rx cough cold market, reflecting difficulties in formulating ER liquids that satisfy current FDA regulations; Tuzistra XR meets these standards. Favourable pricing and reimbursement of the five cough cold products in development by Vernalis would value the addressable market at up to \$3.5bn.

Y/E Jun	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2016	12.0	(23.9)	(16.3)	(3.4)	N/A	N/A
2017	20.8	(23.3)	(21.3)	(3.6)	N/A	N/A
2018e	13.9	(34.0)	(34.0)	(6.3)	N/A	N/A
2019e	26.9	(28.7)	(30.0)	(5.4)	N/A	N/A

Sector: Pharma & healthcare

Price: A\$0.62
Market cap: A\$149m
Market: ASX, OTC QX

Share price graph (A\$)

Company description

Viralytics is a biopharmaceutical company developing Cavatak oncolytic virotherapy to target late-stage melanoma and other solid tumour types. It is trialling Cavatak as a monotherapy and in combination with checkpoint inhibitors.

Price performance

%	1m	3m	12m
Actual	(23.9)	(31.1)	(50.8)
Relative*	(23.8)	(34.9)	(54.7)

* % Relative to local index

Analyst

Dr Dennis Hulme

Viralytics (VLA)

INVESTMENT SUMMARY

Viralytics presented updates at SITC in November highlighting further promising clinical trial data for its Cavatak oncolytic virus immunotherapy. The CAPRA trial of intra-lesional (IL) Cavatak + Keytruda in melanoma reported a 61% response rate in the first 23 of 50 patients. In the MITCI study of IL Cavatak + Yervoy the response rate to date is 57% (8/14) in checkpoint inhibitor naïve patients and 29% (2/7) in patients who had failed single line anti-PD1 therapies - the study is now focused on patients who failed prior single line anti-PD1 therapy. Among 19 evaluable patients in the Keynote 200 trial of IV Cavatak + Keytruda, responses were observed in 3/6 advanced lung cancer and 5/13 bladder cancer patients. Viralytics plans to add 4 new combo studies in the next 6 months in head and neck cancer, melanoma, metastatic uveal melanoma and colorectal cancer. Cash at 30 September was A\$28m.

INDUSTRY OUTLOOK

The FDA approval of Amgen's Imlygic has made oncolytic virotherapy a commercial reality. The December 2016 licence deal between Bristol-Myers Squibb and PsiOxus for its preclinical oncolytic virus NG-348 highlights the potential value of oncolytic virotherapy products; terms included US\$50m upfront and up to US\$886m in milestones.

Y/E Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2016	4.7	(8.5)	(8.0)	(3.8)	N/A	N/A
2017	6.5	(11.7)	(11.3)	(4.7)	N/A	N/A
2018e	5.9	(12.4)	(12.0)	(5.0)	N/A	N/A
2019e	6.1	(12.6)	(12.5)	(5.2)	N/A	N/A

Sector: Pharma & healthcare

Price: US\$3.40
Market cap: US\$90m
Market: NYSE MKT

Share price graph (US\$)



Company description

VolitionRx is a Belgium-based diagnostics company focused on developing blood-based cancer diagnostics based on its proprietary Nu.Q™ technology. Its lead program is in colorectal cancer, which entered the European market in 2017.

Price performance

%	1m	3m	12m
Actual	15.3	20.6	(25.8)
Relative*	12.8	11.9	(37.1)

* % Relative to local index

Analyst

Maxim Jacobs

VolitionRx (VNRX)

INVESTMENT SUMMARY

VolitionRx's proprietary Nu.Q™ technology detects the level and structure of nucleosomes in the blood using one drop of blood serum. It is currently focused on colorectal cancer (CRC), a very large opportunity with around 225 million people eligible for screening (US/EU). VolitionRx will be participating in a 13,500 undiagnosed person trial in the US to gain FDA approval. For Europe, the company plans to receive a CE Mark for their front-line screening panel in Q318.

INDUSTRY OUTLOOK

The blood-based cancer screening market is in its nascent stages with great potential and serves an unmet medical need. Currently there are few, if any, non-invasive screening methods for the vast majority of cancers.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2015	0.0	(10.0)	(9.7)	(54.49)	N/A	N/A
2016	0.0	(12.3)	(12.3)	(53.22)	N/A	N/A
2017e	0.0	(14.0)	(14.0)	(52.69)	N/A	N/A
2018e	0.3	(17.6)	(17.6)	(63.62)	N/A	N/A

Company coverage

Company	Note	Date published
4SC	Update; Outlook	17/05/2017; 30/10/2017
aap Implantate	QuickView; QuickView	17/08/2017; 28/11/2017
Abzena	Update; Update	19/07/2017; 20/09/2017
Acarix	Update; Update	15/05/2017; 13/07/2017
AFT Pharmaceuticals	Update; Outlook	31/05/2017; 12/12/2017
Allium Medical	Update; Update	24/07/2017; 05/09/2017
Angle	Flash; Flash	16/06/2017; 05/07/2017
Arix Bioscience	Initiation	20/04/2017
ASLAN Pharmaceuticals	Initiation	07/11/2017
Atossa Genetics	Update; Outlook	30/05/2017; 16/11/2017
Basilea Pharmaceuticals	Outlook; Update	11/10/2017; 07/12/2017
Bio-Light Life Sciences	Update; Update	12/09/2017; 28/11/2017
Biondavax Pharmaceuticals	Update; Update	13/07/2017; 09/10/2017
Carmat	Flash; Outlook	05/05/2017; 31/07/2017
Cellular Biomedicine Group	Initiation	12/10/2017
Celyad	Flash; Update	04/10/2017; 30/10/2017
Collplant Holdings	Update; Update	18/09/2017; 04/12/2017
Crossject	Update; Outlook	07/04/2017; 03/10/2017
e-Therapeutics	Update; Update	27/07/2017; 04/10/2017
Genkyotex	Outlook; Update	30/05/2017; 06/07/2017
Hutchison China Meditech	Update; ADR Update	18/10/2017; 20/10/2017
Hybrigenics	Update; Update	29/08/2017; 15/11/2017
Immunovia	Update; Update	02/10/2017; 07/12/2017
Immutep	Update; ADR Update	11/12/2017; 12/12/2017
Intec Pharma	Update; Update	27/07/2017; 29/08/2017
International Stem Cell	Update; Update	27/04/2017; 24/05/2017
Kazia Therapeutics	Update; ADR Update	11/09/2017; 11/09/2017
Kiadis Pharma	Update; Update	08/12/2016; 06/01/2017
MagForce	Update; Update	11/08/2017; 06/10/2017
Medigene	Update; Update	03/08/2017; 09/11/2017
Mesoblast	Update; Update	07/06/2017; 23/11/2017
Mologen	Outlook; Update	25/09/2017; 10/11/2017
NetScientific	Update; Outlook	13/07/2017; 11/10/2017
NeuroVive Pharmaceutical	Update; Update	25/08/2017; 14/12/2017
Newron Pharmaceuticals	Flash; Outlook	22/03/2017; 13/10/2017
Nuevolution	Update; Update	28/09/2017; 24/11/2017
Onxeo	Flash; Outlook	14/09/2017; 29/11/2017
Orexigen Therapeutics	Update; Update	17/08/2017; 04/12/2017
Orexo	Update; Update	08/08/2017; 13/12/2017
Oryzon Genomics	Update; Update	22/08/2017; 14/12/2017
Oxford BioMedica	Update; Update	25/07/2017; 01/09/2017
Pacific Edge	Update; Update	13/02/2017; 01/06/2017
Paion	Update; Update	14/08/2017; 10/11/2017
PDL BioPharma	Update; Update	10/08/2017; 20/11/2017
PharmaMar	Update; Update	19/07/2017; 03/11/2017
Photocure	Update; Outlook	01/09/2017; 13/11/2017

Pixium Vision	Update; Update	05/10/2017; 24/10/2017
Pluristem Therapeutics	Update; Update	20/06/2017; 18/10/2017
Probiobrug	Update; Update	16/06/2017; 18/09/2017
Quantum Genomics	Update; Update	27/06/2017; 05/10/2017
Redhill Biopharma	Update; Update	22/08/2017; 27/11/2017
Regeneus	Update; Update	31/05/2017; 07/09/2017
ReNeuron Group	Update; Update	02/05/2017; 06/07/2017
ROVI Laboratorios Farmaceuticos	Initiation; Update	12/07/2017; 14/11/2017
Selvita	Flash; Update	09/10/2017; 28/11/2017
Sierra Oncology	Initiation	18/09/2017
Sunesis Pharmaceuticals	Update; Outlook	03/08/2017; 16/11/2017
SymBio Pharmaceuticals	ADR Update; Update	02/11/2017; 14/12/2017
Targovax	Initiation	08/11/2017
Therapix Biosciences	Update; Update	18/08/2017; 17/11/2017
Transgene	Outlook; Update	18/07/2017; 01/11/2017
TxCell	Update; Update	11/07/2017; 09/10/2017
Vernalis	Update; Outlook	19/07/2017; 22/11/2017
Viralytics	Outlook; Outlook	19/04/2017; 05/12/2017
VolitionRx	Update; Outlook	21/08/2017; 28/11/2017

Investment companies

BB Biotech AG	Investment trust review	09/02/2016; 27/02/2017
Biotech Growth Trust (The)	Investment trust review	20/07/2016; 21/02/2017
International Biotechnology Trust	Investment trust review	03/03/2015; 11/12/2015

QuickViews

To view the QuickViews we publish see the [healthcare](#) sector profile page on our website.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investments Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c)(1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2017. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.

Frankfurt +49 (0)69 78 8076 960
Schumannstrasse 34b
60325 Frankfurt
Germany

London +44 (0)20 3077 5700
280 High Holborn
London, WC1V 7EE
United Kingdom

New York +1 646 653 7026
295 Madison Avenue, 18th Floor
10017, New York
US

Sydney +61 (0)2 8249 8342
Level 12, Office 1205
95 Pitt Street, Sydney
NSW 2000, Australia